

1 Specific Innate Immune Cells Uptake Fetal Antigen and Display Homeostatic Phenotypes in the
2 Maternal Circulation

3 Marcia Arenas-Hernandez^{1,2}, Roberto Romero^{1,3-7}, Meyer Gershater^{1,2}, Li Tao^{1,2},
4 Yi Xu^{1,2}, Valeria Garcia-Flores^{1,2}, Errile Pusod^{1,2}, Derek Miller^{1,2}, Jose Galaz^{1,2},
5 Kenichiro Motomura^{1,2}, George Schwenkel^{1,2}, Robert Para^{1,2},
6 Nardhy Gomez-Lopez^{1,2,8}

7 ¹Perinatology Research Branch, Division of Obstetrics and Maternal-Fetal Medicine,
8 Division of Intramural Research, *Eunice Kennedy Shriver* National Institute of Child
9 Health and Human Development, National Institutes of Health, U. S. Department of
10 Health and Human Services, Bethesda, MD, and Detroit, MI, USA

11 ²Department of Obstetrics and Gynecology, Wayne State University School of
12 Medicine, Detroit, MI, USA

13 ³Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, MI,
14 USA.

15 ⁴Department of Epidemiology and Biostatistics, Michigan State University, East
16 Lansing, MI, USA

17 ⁵Center for Molecular Medicine and Genetics, Wayne State University, Detroit, MI,
18 USA.

19 ⁶Detroit Medical Center, Detroit, MI, USA

20 ⁷Department of Obstetrics and Gynecology, Florida International University, Miami,
21 FL, USA

22 ⁸Department of Biochemistry, Microbiology, and Immunology, Wayne State
23 University School of Medicine, Detroit, MI, USA

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1002/jlb.11051](https://doi.org/10.1002/jlb.11051).

This article is protected by copyright. All rights reserved.

24

25 **Summary Sentence:** Novel interactions demonstrated between specific maternal
26 circulating innate immune cells and fetal antigens that may contribute to the systemic
27 mechanisms of maternal-fetal crosstalk

28

29 **Running Title:** Fetal antigen-carrying innate immune cells

30

31 **Address correspondence to:** Nardhy Gomez-Lopez, PhD, Department of
32 Obstetrics and Gynecology, Wayne State University, School of Medicine,
33 Perinatology Research Branch, NICHD/NIH/DHHS, 275 E Hancock St, Detroit,
34 Michigan 48201 USA, Tel: 313-577-8904, Fax: 313-993-6769, Email: [nardhy.gomez-](mailto:nardhy.gomez-lopez@wayne.edu)
35 lopez@wayne.edu; ngomezlo@med.wayne.edu

36

37 **Keywords:** human, innate immune cells, maternal-fetal tolerance, mice, OVA,
38 peripheral blood, pregnancy

39 **ABBREVIATIONS**

- 40 APC: Antigen-presenting cell
41 GFP: green fluorescent protein
42 HLA: human leukocyte antigen
43 IL: interleukin
44 IFN γ : interferon gamma
45 MHC-II: major histocompatibility complex class II
46 NET: neutrophil extracellular trap
47 NK cell: natural killer cell
48 OVA: ovalbumin
49 PP: postpartum
50 ROS: reactive oxygen species
51 STBM: syncytiotrophoblast-derived microparticles
52 TGF β : transforming growth factor beta
53 TNF: tumor necrosis factor

54 **ABSTRACT**

55 Pregnancy represents a period when the mother undergoes significant
56 immunological changes to promote tolerance of the fetal semi-allograft. Such
57 tolerance results from the exposure of the maternal immune system to fetal antigens,
58 a process that has been widely investigated at the maternal-fetal interface and the
59 adjacent draining lymph nodes. However, the peripheral mechanisms of maternal-
60 fetal crosstalk are poorly understood. Herein, we hypothesized that specific innate
61 immune cells interact with fetal antigens in the maternal circulation. To test this
62 hypothesis, we utilized a mouse model of transgenic male mice that express the
63 chicken ovalbumin (OVA) antigen under the beta-actin promoter, which were
64 allogeneically mated with wild type females to allow for the tracking of the fetal
65 antigen. Fetal antigen-carrying Ly6G⁺ and F4/80⁺ cells were identified in the
66 maternal circulation, where they were more abundant in the second half of
67 pregnancy. Such innate immune cells displayed unique phenotypes: while Ly6G⁺
68 cells expressed high levels of MHC-II and CD80 together with low levels of pro-
69 inflammatory cytokines, F4/80⁺ cells upregulated the expression of CD86 as well as
70 the anti-inflammatory cytokines IL-10 and TGF β . *In vitro* studies using allogeneic
71 GFP⁺ placental particles revealed that maternal peripheral Ly6G⁺ and F4/80⁺ cells
72 phagocytose fetal antigens in mid and late murine pregnancy. Importantly,
73 cytotrophoblast-derived particles were also *in vitro* engulfed by CD15⁺ and CD14⁺
74 cells from pregnant women, providing translational evidence that this process also
75 occurs in humans. Collectively, this study demonstrates novel interactions between
76 specific maternal circulating innate immune cells and fetal antigens, thereby
77 shedding light on the systemic mechanisms of maternal-fetal crosstalk.

78 INTRODUCTION

79 Pregnancy represents a period of significant immunological changes in the
80 mother that allow her to tolerate the fetal semi-allograft [1-5]. Among these
81 adaptations, the best-characterized are those that occur at the site of contact
82 between the maternal and fetal tissues, i.e. the maternal-fetal interface [6]. In this
83 compartment and the adjoining tissues (e.g. the uterine-draining lymph nodes) [7-
84 14], exposure of the maternal immune system to fetus-derived antigens initiates the
85 establishment of tolerance [15-17] by promoting the induction of regulatory T cells
86 (Tregs) [8, 18-27]. Other mechanisms of maternal-fetal tolerance may include
87 effector T-cell exhaustion [28, 29] and the enrichment of the homeostatic immune
88 microenvironment by innate immunoregulatory cells [30-37]. The placenta also
89 contributes to local tolerance by expressing immunomodulatory non-classical MHC
90 molecules (e.g. HLA-G) that inhibit NK cell responses [38-40] as well as inhibitory
91 checkpoint ligands such as PD-L1 [41, 42]. Together, these and other [4, 43] cellular
92 processes mediate the local mechanisms of maternal-fetal tolerance.

93 An established hallmark of pregnancy is the transfer of fetal cells into the
94 maternal circulation [44-46] (and vice versa [47-50]), a phenomenon termed fetal or
95 maternal microchimerism, respectively. Fetal microchimerism is detected as early as
96 seven weeks of gestation [46], and the abundance of such cells (as well as their
97 genetic material) steadily increase throughout pregnancy [46]. Such a process not
98 only participates in the mechanisms of maternal-fetal tolerance [51, 52] but can also
99 have long-lasting effects, given that fetal or maternal cells are observed in the
100 circulation of the mother and offspring, respectively, for decades after delivery [45,
101 47]. In addition to fetal cells, the placenta can also release microparticles and
102 exosomes into the maternal circulation, either due to apoptotic turnover or by active

103 secretion [53-63]. Specifically, placenta-derived particles serve as modulators of
104 maternal systemic immune responses [54-56, 59, 60, 64-67] and, similar to fetal
105 cells, their concentrations increase as gestation progresses [53, 56, 68]. However,
106 the interactions between placenta-derived microparticles and maternal circulating
107 immune cells have not been well explored.

108 Previous studies have established that the phenotypes and functions of
109 neutrophils and monocytes in the maternal circulation are highly impacted
110 throughout pregnancy [69-71]. Neutrophils from pregnant women exhibit an
111 enhanced state of activation as evidenced by the increased expression of cell
112 surface markers (e.g. CD14 and CD64) [69, 70], higher basal intracellular reactive
113 oxygen species (iROS) levels [69, 70, 72] and reactive oxygen metabolite release
114 [73], and altered phagocytic activity [74-76] compared to those from non-pregnant
115 women. Similarly, monocytes from pregnant women display increased cell surface
116 marker expression (e.g. CD11b, CD18 and CD64) [69, 70, 77, 78], greater basal
117 iROS production [69, 70], enhanced cytokine responses [56, 79], and perturbed
118 phagocytic activity [75, 80] compared to those from non-pregnant women. Yet,
119 whether such innate immune cells interact with fetal-derived antigens in the maternal
120 circulation is unknown.

121 The aim of this study was to investigate whether maternal circulating Ly6G+
122 cells (i.e. neutrophils) and F4/80+ cells (i.e. monocytes/macrophages) capture fetal
123 antigens throughout gestation. Specifically, we utilized transgenic male mice that
124 express the chicken ovalbumin (OVA) antigen under the beta-actin promoter, which
125 were allogeneically mated with wild type females to allow for the tracking of the fetal
126 antigen [9, 81-83]. First, we explored the localization of the fetal antigen in Ly6G+
127 and F4/80+ cells in the myometrium and periphery as well as their kinetics

128 throughout pregnancy. Second, using flow cytometry, we characterized the
129 phenotypes and cytokine profiles of fetal antigen-carrying Ly6G+ and F4/80+ cells
130 and confirmed their maternal origin. Third, functional *in vitro* studies were utilized to
131 investigate whether the fetal antigen can be phagocytosed by maternal peripheral
132 Ly6G+ and F4/80+ cells during mid and late murine gestation. Lastly, to demonstrate
133 the translational value of our findings in mice, we performed *in vitro* studies using
134 maternal peripheral CD15+ cells (i.e. neutrophils) and CD14+ cells (i.e. monocytes)
135 from second and third trimester pregnancies to explore whether cytotrophoblast-
136 derived particles can also be engulfed by such innate immune cells.

137

Author Manuscript

138 MATERIALS AND METHODS

139 Mice

140 C57BL/6-Tg(CAG-OVAL)916Jen/J (Act-mOVA II) (hereafter referred to as B6
141 CAG-OVA) male, BALB/cByJ (BALB/c) female and male, C57BL/6 female and
142 C57BL/6 male (hereafter referred to as B6 non-CAG-OVA), C57BL/6 Actb-Egfp
143 (GFP+) male, and DBA/2 female mice were purchased from The Jackson Laboratory
144 (Bar Harbor, ME), bred in the animal care facility at the C.S. Mott Center for Human
145 Growth and Development, Wayne State University, Detroit, MI, and housed under a
146 circadian cycle (light:dark = 12:12 h). Eight- to twelve-week-old females were
147 examined daily between 8:00 and 9:00 am for the presence of a vaginal plug, which
148 indicated 0.5 days *post coitum* (dpc). Upon observation of vaginal plugs, female mice
149 were removed from mating cages and housed separately. Pregnancy at 4.5 dpc was
150 confirmed *ex vivo* by using trypan blue to stain the implantation sites, followed by
151 washing with 1X phosphate-buffered saline (PBS; Fisher Scientific Chemicals, Fair
152 Lawn, NJ). Pregnancy at 10.5 dpc was confirmed by a weight gain of ≥ 2 g.
153 Postpartum BALB/c females (PP; 48 - 60 h after delivery) were also included in this
154 study. All experiments were approved by the Institutional Animal Care and Use
155 Committee at Wayne State University (Protocol No. A 09-08-12, A 07-03-15, 18-03-
156 0584, and 21-04-3506).

157

158 Human subjects and clinical specimens

159 Human maternal peripheral blood samples were obtained at the Perinatology
160 Research Branch, an intramural program of the *Eunice Kennedy Shriver* National
161 Institute of Child Health and Human Development, National Institutes of Health, U.S.
162 Department of Health and Human Services, Wayne State University (Detroit, MI),

163 and the Detroit Medical Center (Detroit, MI). The collection and use of human
164 materials for research purposes were approved by the Institutional Review Boards of
165 Wayne State University and the National Institute of Child Health and Human
166 Development. All participating women provided written informed consent prior to
167 sample collection. Samples were obtained from healthy women with normal
168 pregnancies in the second or third trimester.

169

170 **Hematoxylin & eosin staining of fetal and myometrial tissues**

171 Fetuses and the surrounding myometrial tissues were collected from dams at
172 10.5 dpc, 16.5 dpc, and 18.5 dpc and placed into Tissue Tek OCT freezing medium
173 (Sakura Finetek USA, Inc., Torrance, CA) (n = 3 - 10 each). Sagittal cuts of 16 μ m
174 thickness were taken from each fetus. Slices were mounted on slides and fixed with
175 4% paraformaldehyde (Electron Microscopy Sciences, Hatfield, PA) for 30 minutes
176 (min) at 4°C. Slides were stained with hematoxylin (Thermo Fisher Scientific,
177 Waltham, MA) for 1 min and 10 seconds (s), and immersed in clarifier for 5 s and
178 blueing agent for 20 s, rinsing the slides with distilled water after each step. The
179 slides were then stained with eosin (Thermo Fisher Scientific) for 45 s and
180 dehydrated in a series of alcohol baths and xylene prior to applying coverslip. All
181 hematoxylin & eosin (H&E) images were taken using the Vectra Polaris Multispectral
182 Imaging System (PerkinElmer, Waltham, MA, USA) at 4x magnification.

183

184 **Confocal microscopy of fetal and myometrial tissues**

185 Fetuses and the surrounding myometrial tissues were collected from dams at
186 10.5 dpc, 16.5 dpc, and 18.5 dpc and placed into Tissue Tek OCT freezing medium
187 (n = 3 - 10 each). Sagittal cuts of 16 μ m thickness were taken from each fetus. Slices

188 were mounted on slides and fixed with 4% paraformaldehyde (Electron Microscopy
189 Sciences) in 1X phosphate buffered saline (PBS; Life Technologies, Grand Island,
190 NY) for 30 min at 4°C. Slides were then rinsed with 1X PBS (Life Technologies,
191 Grand Island, NY), permeabilized with 0.25% Triton X-100 (Promega Corporation,
192 Madison, WI) for 5 min at room temperature (RT), rinsed again with 1X PBS and
193 blocked with 5% bovine serum albumin (BSA; Sigma-Aldrich, St Louis, MO) diluted
194 in 1X PBS for 30 min at RT. The primary OVA-FITC (Cat #: 200-4233-0101,
195 Rockland Immunochemicals, Inc. Gilbertsville, PA, USA) antibody or rabbit IgG
196 isotype control was added and the slides were incubated for 1 h at RT. The slides
197 were washed with 1X PBS, CD11b-Alexa Fluor 594 antibody (Cat #: 101254,
198 BioLegend, San Diego, CA) was added, and the slides were incubated for 30 min at
199 RT. After washing, slides were mounted with ProLong Gold Mounting medium with
200 4',6-diamidino-2-phenylindole (DAPI) (Life Technologies). Immunofluorescence was
201 visualized using a Zeiss LSM 780 laser scanning confocal microscope (Carl Zeiss
202 Microscopy, Jena, Germany) at the Microscopy, Imaging, and Cytometry Resources
203 Core of Wayne State University School of Medicine (<https://micr.med.wayne.edu/>).
204 The 561 nm line of an "in-tune" tunable white laser was used to excite Alexa Fluor
205 594, the 488 nm line of the tunable white laser to excite FITC, and the 405 nm diode
206 laser to excite DAPI.

207

208 **Cell sorting**

209 Dams at 10.5 dpc and 18.5 dpc were euthanized and peripheral blood was
210 obtained by cardiac puncture (n = 10 each). Peripheral leukocytes were incubated
211 with the CD16/CD32 monoclonal antibody (mAb) (FcγIII/II receptor; BD Biosciences,
212 San Jose, CA) followed by staining using CD11b-PECF594, Ly6G-APC-Cy7 and

213 F4/80-PE mAbs (BD Biosciences), after which the cell suspensions underwent
214 intracellular staining with either OVA-FITC antibody or rabbit IgG-FITC isotype
215 control. Cells were resuspended in 500 μ L of FACS buffer and sorted using a BD
216 FACSAria cell sorter (BD Biosciences) and BD FACSDiva Software Version 6.1.3.
217 The sorted CD11b+Ly6G+OVA+ or CD11b+F4/80+OVA+ cells were then
218 resuspended with 200 μ L of FACS buffer. Cytospin slides of sorted cells were
219 prepared using Fisherbrand Superfrost microscope slides (Thermo Fisher Scientific)
220 and a Shandon Cytospin 3 cytocentrifuge (Thermo Fisher Scientific) at 800 rpm for 5
221 min. After centrifugation, all slides were washed with 1X PBS and the cells were
222 fixed with 4% paraformaldehyde for 20 min. After fixation, the slides were washed
223 with 1X PBS, dried, and mounted using ProLong Diamond Antifade Mountant with
224 DAPI. Images were obtained with an Olympus BX60 fluorescence microscope at 40x
225 magnification with digital zoom.

226

227 **Leukocyte isolation from the maternal peripheral blood and myometrium**

228 *Identification of fetal antigen-carrying immune cells throughout pregnancy and*
229 *postpartum*

230 Dams mated with B6 CAG-OVA or non-CAG-OVA males were euthanized at
231 4.5 dpc, 10.5 dpc, 16.5 dpc, 18.5 dpc, and in the postpartum period and peripheral
232 blood was obtained by cardiac puncture. Non-pregnant females were also included
233 as controls. Myometrial tissues from the implantation sites were collected (n = 2 – 14
234 each), and images of the uterine horns were taken. Isolation of leukocytes from
235 myometrial tissues was performed as previously described [84]. Briefly, tissues were
236 minced using fine scissors and enzymatically digested with StemPro Cell
237 Dissociation Reagent (Life Technologies) for 35 min at 37°C. Leukocyte suspensions

238 were filtered using a 100- μ m cell strainer (Fisherbrand; Fisher Scientific, Fair Lawn,
239 NY) and washed with FACS buffer [0.1% BSA and 0.05% sodium azide (Fisher
240 Scientific Chemicals) in 1X PBS] immediately prior to immunophenotyping.

241

242 *Immunophenotyping of fetal antigen-carrying immune cells in mid and late*
243 *pregnancy*

244 Dams at 10.5 dpc (mid pregnancy) and 16.5 dpc (late pregnancy) were
245 euthanized and peripheral blood was obtained by cardiac puncture (n = 9 – 12 each).
246 Myometrial tissues from the implantation sites were collected (n = 9 – 11 each).
247 Isolation of leukocytes from myometrial tissues was performed, as previously
248 described [84]. Isolated leukocytes were utilized for immunophenotyping.

249

250 **Immunophenotyping of leukocytes in the maternal peripheral blood and**
251 **myometrium**

252 *Identification of fetal antigen-carrying immune cells throughout pregnancy and*
253 *postpartum*

254 Maternal peripheral blood (150 μ L) and leukocyte suspensions from the
255 myometrium were centrifuged at 1250 x g for 10 min at 4°C, and cell pellets were
256 incubated with the CD16/CD32 mAb (Fc γ III/II receptor; BD Biosciences) for 10 min,
257 and subsequently incubated with specific fluorochrome-conjugated anti-mouse mAbs
258 (Table S1) for 30 min at 4°C in the dark. After washing, the cells were fixed and
259 permeabilized with the BD Cytofix/Cytoperm kit (BD Biosciences) prior to staining
260 with intracellular Abs. For intracellular staining, OVA-FITC antibody or its isotype
261 control (Table S1) were then added to the cells, which were then incubated for 30
262 min at 4°C in the dark. Following staining, cells were acquired using the BD

263 LSRFortessa flow cytometer (BD Biosciences) and FACSDiva 8.0 software (BD
264 Biosciences). Immunophenotyping included the identification of CD45+Ly6G+OVA+
265 (or CD45+Ly6G+OVA-) cells and CD45+F4/80+OVA+ (or CD45+F4/80+OVA-) cells
266 in the myometrium and peripheral blood. Data were analyzed using FlowJo software
267 v10 (FlowJo, Ashland, OR).

268

269 *Immunophenotyping of fetal antigen-carrying immune cells in mid and late*
270 *pregnancy*

271 Maternal peripheral blood (150 μ L) and leukocyte suspensions from the
272 myometrium were stained using the LIVE/DEAD Fixable Blue Dead Cell Stain Kit
273 (Life Technologies) or Fixable Viability Stain 510 (BD Biosciences) prior to incubation
274 with extracellular and intracellular mAbs, as described above. Immunophenotyping
275 included the identification of surface markers (MHC-II, CD80, CD86, CD206, and
276 CD62L) and cytokines (IFN γ , TNF α , IL-10, and TGF β) expressed by viable
277 CD11b+Ly6G+OVA- or CD11b+Ly6G+OVA+ cells and CD11b+F4/80+OVA- or
278 CD11b+F4/80+OVA+ cells in the maternal peripheral blood at mid (10.5 dpc) and
279 late (16.5 dpc) pregnancy. The expression of the same cell surface markers and
280 cytokines were evaluated on viable CD11b+Ly6G+OVA+ cells and
281 CD11b+F4/80+OVA+ cells in the myometrial tissues at mid (10.5 dpc) and late (16.5
282 dpc) pregnancy. The expression of the MHC class I molecules H2K^b and H2K^d was
283 evaluated on viable CD11b+Ly6G+OVA+ and CD11b+F4/80+OVA+ cells from the
284 maternal peripheral blood (50 μ L) at mid-gestation (10.5 dpc). Data were analyzed
285 using FlowJo software v10.

286

287 **Phagocytosis assays**

288 *Generation of GFP+ placental particles*

289 To obtain GFP+ placental particles, DBA/2 female mice were mated with
290 GFP+ males and the placentas were collected at 17.5 dpc. After collection, the
291 placentas were placed in a Petri dish with PBS and the expression of GFP was
292 determined by *ex vivo* imaging with the IVIS Spectrum *in vivo* imaging system
293 (PerkinElmer) [85]. An excitation filter of 465 nm and an emission filter of 520 nm
294 were used to determine GFP expression. GFP+ placenta-derived particles were
295 prepared using a mechanical tissue homogenizer. Whole cells and large cell
296 fragments were removed by centrifugation at 1,000 x g for 5 min. Tissue
297 homogenates from one placenta were divided into four aliquots, and GFP+ placenta-
298 derived particles were collected by centrifugation at 16,000 x g for 5 min. One aliquot
299 of placenta-derived particles was opsonized with 50 μ L autologous plasma for 30
300 min at 37°C and used for phagocytosis assays.

301

302 *Phagocytosis of placenta-derived particles or E. coli by murine maternal peripheral* 303 *Ly6G+ and F4/80+ cells*

304 Whole blood samples were collected from pregnant C57BL/6 dams (mated
305 with BALB/c males) at 10.5 or 16.5 dpc (n = 6 each). Whole maternal blood (50 μ L)
306 was then incubated with 10 μ L of GFP+ placenta-derived particles or 10 μ L of
307 pHrodo™ Green *E. coli* BioParticles (Life Technologies) for 15 min at 37°C or on ice.
308 After incubation, the cells were washed with FACS stain buffer (BD Biosciences) and
309 centrifuged at 400 x g for 5 min. The cells were then incubated with anti-mouse
310 CD11b Alexa Fluor594, anti-mouse F4/80 APC, and anti-mouse Ly6G APC-Cy7
311 antibodies (Table S1) in FACS staining buffer (BD Biosciences) for 30 minutes at
312 4°C in the dark. After incubation, erythrocytes were lysed using Ammonium-Chloride-

313 Potassium (ACK) lysing buffer (Lonza, Walkersville, MD), and the resulting
314 leukocytes were collected after centrifugation at 400 x g for 5 min. Finally, the cells
315 were washed and resuspended in 500 μ L of FACS staining buffer and acquired
316 using the BD LSRFortessa flow cytometer and FACSDiva 9 software. The analysis
317 and figures were performed using FlowJo software version 10. The percentage of
318 active phagocytic cells was calculated as the percentage of phagocytic cells at 37°C
319 minus the percentage of phagocytic cells on ice.

320

321 *Phagocytosis of cytotrophoblast-derived particles or E. coli by human maternal*
322 *peripheral CD15+ and CD14+ cells*

323 Human peripheral blood samples were collected from healthy pregnant
324 women in the second or third trimester by venipuncture into collection tubes
325 containing EDTA (n = 4 – 6 each). Peripheral blood mononuclear cells (PBMCs) and
326 polymorphonuclear neutrophils (PMNs) were isolated using Polymorphprep™ (Alere
327 Technologies, Oslo, Norway), following the manufacturer's instructions. After
328 gradient separation, PBMCs and PMNs were washed with 1X PBS (Life
329 Technologies). Cells were resuspended in RPMI 1640 medium (Life Technologies)
330 supplemented with 5% human serum (Sigma Aldrich) and 1% penicillin/streptomycin
331 antibiotics (Life Technologies) at a concentration of 5×10^6 cells/mL. Swan71 human
332 first-trimester cytotrophoblast cells [86] were maintained in Dulbecco's modified
333 Eagle's medium (Life Technologies) supplemented with 10% fetal bovine serum (Life
334 Technologies) and 1% penicillin/streptomycin antibiotics. Swan71 cells were
335 collected and labeled using Vybrant® DiO cell-labeling solution (Life Technologies),
336 and then 1×10^7 DiO-labelled Swan71 cells were homogenized using a mechanical
337 tissue homogenizer. Whole cells and cell nuclei were removed by centrifugation at

338 2000 x g for 5 min, after which the labelled Swan71-derived particles were collected
339 by centrifugation at 16,000 x g for 5 min. The Swan71-derived particles were
340 opsonized with 100 μ L human sera for 30 min at 37°C. Then, $5 \times 10^5/100\mu$ L of
341 combined PBMCs and PMNs were incubated with 20 μ L of Swan71-derived particles
342 or 20 μ L of pHrodo™ Green *E. coli* BioParticles for 15 min at either 37°C or on ice.
343 After incubation, the PBMCs and PMNs were washed and centrifuged at 300 x g for
344 5 min followed by incubation with mouse anti-human CD15 BV650 (BD Biosciences)
345 and mouse anti-human CD14 BUV395 (BD Biosciences) antibodies in FACS staining
346 buffer for 30 minutes at 4°C in the dark. Finally, the cells were washed and
347 resuspended in 500 μ L of FACS staining buffer and acquired using the BD
348 LSRFortessa flow cytometer and FACSDiva 9 software. The analysis and figures
349 were performed using FlowJo software version 10. The percentage of active
350 phagocytic cells was calculated as the percentage of phagocytic cells at 37°C minus
351 the percentage of phagocytic cells on ice.

352

353 **Immunofluorescence and confocal microscopy of *in vitro* phagocytosis**

354 Murine CD11b+ leukocytes were isolated from whole blood using CD11b
355 MicroBeads (Miltenyi Biotec, San Diego, CA). Briefly, 300 μ L mouse whole blood
356 was lysed with ACK lysing buffer for 5 min on ice to remove erythrocytes.
357 Leukocytes were collected by centrifugation at 400 x g for 5 min. CD11b+ cells were
358 selected by isolation using CD11b MicroBeads, following the manufacturer's
359 instructions. CD11b+ cells were placed into eight-well Lab-Tek chamber slides
360 (Thermo Fisher Scientific) with RPMI 1640 medium (Life Technologies). Chamber
361 slides were incubated for 15 min at 37°C. After incubation, 10 μ L of GFP+ placental
362 fragments or 10 μ L pHrodo™ Green *E. coli* BioParticles were added to RPMI 1640

363 medium for 30 min at 37°C. Cells were then fixed with 4% paraformaldehyde and
364 immediately used for immunofluorescence staining. Next, slides were blocked using
365 Antibody Diluent/Block (PerkinElmer, Boston, MA) for 30 min at RT. Slides were then
366 incubated with rat anti-mouse CD11b Alexa Fluor 594 followed by incubation with
367 goat anti-rat IgG Alexa Fluor 594 (Table S1). Immunofluorescence signal was
368 visualized using a Zeiss LSM 780 laser scanning confocal microscope as described
369 above. Immunofluorescence signals for Alexa Fluor 647, Alexa Fluor 594, and green
370 fluorescence were excited with a 633 nm HeNe laser, a 550 nm HeNe laser, and a
371 488 nm line of multiline argon laser, respectively. The DAPI signal was excited with a
372 405 nm diode laser.

373 Maternal PBMCs and PMNs were seeded into a four-well Lab-Tek chamber
374 slide with RPMI 1640 medium supplemented with 5% human serum and 1%
375 penicillin/streptomycin antibiotics at a concentration of 5×10^6 cells/mL. Cells were
376 incubated for 1 h at 37°C to allow for attachment to the chamber slide. Unattached
377 cells were then removed, and new medium was added. Next, 20 μ L of Swan71
378 fragments or 20 μ L of pHrodo™ Green *E. coli* BioParticles were added to RPMI 1640
379 medium for 2 h at 37°C. After incubation, cells were then fixed with 4%
380 paraformaldehyde and washed with 1X PBS. Next, slides were blocked using
381 Antibody Diluent/Block (PerkinElmer, Boston, MA) for 30 min at RT. Slides were then
382 incubated with mouse anti-human CD14 (BD Biosciences) at RT for 1 h. Following
383 incubation, slides were washed with PBST [1X PBS containing 0.1% Tween 20
384 (Sigma-Aldrich)] and goat anti-mouse IgG Alexa Fluor 594 (BD Biosciences) was
385 added and incubated for 30 min at RT. Next, slides were incubated with mouse anti-
386 human CD15 Alexa Fluor 647 (BD Biosciences) for another hour at RT. Finally,
387 slides were washed and mounted with Prolong Gold Antifade Mountant with DAPI.

388 Immunofluorescence signals were visualized using a Zeiss LSM 780 laser scanning
389 confocal microscope as described above.

390

391 **Statistics**

392 Statistical analyses were performed using SPSS v19.0 (IBM Corporation,
393 Armonk, NY) or GraphPad Prism version 8.0.1 for Windows (GraphPad Software,
394 San Diego, CA). The Shapiro-Wilk test was performed to determine the normality of
395 the data. For the proportions of immune cells carrying the fetal antigen throughout
396 pregnancy, the Shapiro-Wilk normality test was applied, after which the statistical
397 significance between groups was determined using the Kruskal-Wallis test followed
398 by Dunn's post-hoc test. The statistical significance between groups for the
399 immunophenotyping at 10.5 dpc and 16.5 dpc as well as the human and murine
400 phagocytosis experiments was determined using Mann–Whitney U-tests. A p value \leq
401 0.05 was considered statistically significant.

402

403 **Online Supplemental Material**

404 **Table S1. List of antibodies used for immunophenotyping and microscopy**

405

406 **Fig. S1. Isotype staining control for the localization of Ly6G+ and F4/80+ cells**
407 **in the myometrial tissues in the second half of pregnancy**

408

409 **Fig. S2. Ly6G+ and F4/80+ cells in the myometrial tissues in the second half of**
410 **pregnancy (OVA antibody staining control)**

411

412 **Fig. S3. Expression of OVA in maternal circulating T cells and proportions of**
413 **Ly6G+ and F4/80+ cells in the myometrial tissues and maternal circulation**
414 **from non-pregnant, pregnant, and post-partum dams**

415

416 **Fig. S4. Immunophenotyping of fetal antigen-carrying Ly6G+ and F4/80+ cells**
417 **in the myometrial tissues during mid and late gestation**

418

419 **Fig. S5. Phagocytosis of *Escherichia coli* by murine maternal Ly6G+ or F4/80+**
420 **cells and human maternal CD15+ or CD14+ cells in the second and third**
421 **trimester of pregnancy**

Author Manuscript

422 RESULTS

423 Localization of the fetal antigen to Ly6G+ and F4/80+ cells in the myometrium 424 and maternal circulation throughout pregnancy

425 Fetal antigens are released into the maternal circulation [44-46], a fraction of
426 which are localized in the reproductive tissues [87, 88]. However, whether such
427 antigens are found in tissue-resident innate immune cells is unknown. Herein, we
428 first investigated the presence of the fetal antigen in Ly6G+ and F4/80+ cells residing
429 in the myometrium surrounding the embryo using a model of B6 CAG-OVA males
430 mated with wild type BALB/c females (Fig. 1A). The myometrial tissues surrounding
431 the fetus and placenta were collected at 10.5 days *post coitum* (dpc), 16.5 dpc, or
432 18.5 dpc (Fig. 1A). H&E staining provided an anatomical overview to serve as a
433 reference for subsequent immunofluorescence staining (Fig. 1A). Given that CD11b
434 (a cell surface marker for cells of myeloid origin) is expressed by both monocytes
435 and granulocytes [89-93], we evaluated the intracellular expression of the OVA
436 protein inside CD11b+ cells in the myometrial tissues from 10.5 dpc, 16.5 dpc, and
437 18.5 dpc. Confocal microscopy revealed localization of the OVA protein inside of
438 myeloid cells in the myometrium, suggesting that local innate immune cells carry the
439 fetal antigen (Fig. 1A). Isotype staining confirmed that the visualization of the OVA
440 protein within such cells was not due to non-specific staining (Fig. S1). To further
441 demonstrate the specificity of the observed OVA signal in myometrial CD11b+ cells,
442 we similarly evaluated the intracellular expression of the OVA protein in dams mated
443 with B6 non-CAG-OVA males (Fig. S2). A positive OVA signal was not observed in
444 myometrial CD11b+ cells from dams mated with B6 non-CAG-OVA males when
445 using the anti-OVA antibody (Fig. S1A) or isotype control (Fig. S2B).

446 Next, we explored whether fetal antigen-carrying cells could be detected and
447 visualized in the maternal circulation during mid-pregnancy (10.5 dpc). Ly6G+OVA+
448 and F4/80+OVA+ cells were detected in the maternal circulation. Intracellular
449 immunofluorescence staining was utilized to confirm the expression of OVA in sorted
450 innate immune cells (Fig. 1B). These findings show that innate immune cells carrying
451 the fetal antigen are present in the myometrium and can be detected in the maternal
452 circulation.

453

454 **The local and systemic proportions of fetal antigen-carrying Ly6G+ and F4/80+** 455 **cells change throughout pregnancy**

456 Given that the fetal antigen (OVA) was detected in Ly6G+ and F4/80+ cells in
457 the myometrium and maternal circulation, we next investigated whether the
458 proportions of these OVA+ cells changed throughout pregnancy. B6 CAG-OVA
459 males were mated with wild type BALB/c (non-CAG-OVA) females, and the
460 myometrial tissues and maternal peripheral blood were collected at 4.5 dpc (early
461 pregnancy; Trypan blue staining was utilized to detect implantation sites), 10.5 dpc
462 (mid pregnancy), 16.5 dpc (late pregnancy), and 18.5 dpc (term pregnancy) as well
463 as postpartum (PP) (Fig. 2A). The populations of Ly6G+OVA+ and F4/80+OVA+
464 cells were determined in the myometrium and maternal circulation at each time point.
465 The intracellular presence of OVA by CD4+ and CD8+ T cells was also examined,
466 but these cells did not carry the fetal antigen in the maternal circulation (Fig. S3A).

467 The proportion of myometrial Ly6G+OVA+ cells drastically increased from 4.5
468 dpc to 10.5 dpc and was largely maintained until term (18.5 dpc), subsequently
469 declining in the PP period (Fig. 2B). The proportion of myometrial F4/80+OVA+ cells
470 peaked at 10.5 dpc and showed a slower decline from this point to PP (Fig. 2C). In

471 the maternal circulation, a large proportion of Ly6G+OVA+ cells was observed at
472 each time point, including PP (Fig. 2D). The proportion of peripheral Ly6G+OVA+
473 cells followed a similar trajectory to that in the myometrial tissues but with less
474 variation, gradually increasing from 4.5 dpc to 10.5 dpc and then modestly declining
475 in the PP period (Fig. 2D). In contrast, the proportion of F4/80+OVA+ cells in the
476 maternal circulation was lower than that of Ly6G+OVA+ cells at each time point, yet
477 followed an overall similar trend (Fig. 2E). To confirm the presence of OVA+ cells in
478 the myometrium and maternal circulation, we repeated the above experiment using
479 tissues obtained from dams mated with B6 non-CAG-OVA males (Fig. S3B). A
480 positive OVA signal was not detected in Ly6G+ or F4/80+ cells in the myometrial
481 tissues (Fig. S3C & D) nor in the peripheral blood (Fig. S3E & F).

482 Fetal cells are found in the maternal circulation during pregnancy and persist
483 through the post-partum period; yet, these are rare [44, 45, 47]. Therefore, we
484 confirmed the maternal origin of phagocytes carrying the OVA antigen in the
485 myometrium and peripheral blood (Fig. 3A & B). Ly6G+OVA+ and F4/80+OVA+ cells
486 in both the myometrium (Fig. 3C) and periphery (Fig. 3D) expressed H2K^d (maternal
487 MHC-I haplotype) and lacked H2K^b (paternal MHC-I haplotype), indicating their
488 maternal origin.

489 Together, these results indicate that the proportions of fetal antigen-carrying
490 Ly6G+ cells (neutrophils) and F4/80+ cells (monocytes/macrophages) in the
491 maternal circulation and myometrium are highest during the second half of
492 pregnancy and decline after delivery. Hereafter, we primarily focused on
493 investigating the phenotypic and functional properties of such innate immune cells in
494 the maternal circulation to further explore systemic maternal-fetal crosstalk, a poorly
495 understood phenomenon.

496

497 **Fetal antigen-carrying Ly6G⁺ and F4/80⁺ cells in the maternal circulation**
498 **display unique phenotypes**

499 We next characterized the phenotypes of Ly6G⁺OVA⁺ and F4/80⁺OVA⁺ cells
500 in the maternal circulation during mid and late pregnancy to determine whether these
501 cells were distinct from their OVA⁻ counterparts. Maternal peripheral blood was
502 collected at 10.5 dpc and 16.5 dpc from wild type BALB/c females mated with B6
503 CAG-OVA males, and immunophenotyping of Ly6G⁺OVA⁺ or Ly6G⁺OVA⁻ cells and
504 F4/80⁺OVA⁺ or F4/80⁺OVA⁻ cells was performed (Fig. 4A). We first examined the
505 expression of major histocompatibility complex class II (MHC-II), an essential
506 molecule for antigen presentation by antigen-presenting cells (APCs) [94], and found
507 that the expression of MHC-II was significantly higher on Ly6G⁺OVA⁺ cells
508 compared to Ly6G⁺OVA⁻ cells in the maternal circulation at 10.5 dpc and tended to
509 increase at 16.5 dpc (Fig. 4B). A similar trend was observed for the expression of
510 MHC-II by F4/80⁺OVA⁺ cells, although this did not reach significance (Fig. 4C). We
511 also investigated the expression of the co-stimulatory molecules CD80 and CD86
512 [95] by OVA⁺ and OVA⁻ innate immune cells. The expression of CD80 by
513 Ly6G⁺OVA⁺ cells was elevated in the maternal circulation (peripheral blood)
514 compared to Ly6G⁺OVA⁻ cells at both 10.5 dpc and 16.5 dpc (Fig. 4D). However,
515 the expression of CD80 by F4/80⁺OVA⁺ cells was similar to that of F4/80⁺OVA⁻
516 cells (Fig. 4E). Although the expression of CD86 by Ly6G⁺OVA⁺ cells did not differ
517 from that of Ly6G⁺OVA⁻ cells (Fig. 4F), the expression of this co-stimulatory
518 molecule was increased by F4/80⁺OVA⁺ cells compared to F4/80⁺OVA⁻ cells at
519 10.5 dpc and 16.5 dpc (Fig. 4G). No significant differences were observed in the

520 expression of the activation markers CD206 [96-99] and CD62L [100-103] by OVA+
521 and OVA- innate immune cells (Fig. 4H-K).

522 We also performed immunophenotyping of myometrial Ly6G+OVA+ and
523 F4/80+OVA+ cells to measure expression of the molecules that were determined in
524 OVA+ innate immune cells in the maternal circulation (Fig. S4A). Comparative
525 analysis between OVA+ and OVA- immune cells in the myometrial tissues was not
526 possible since very few OVA- leukocytes were found in these tissues. Therefore, we
527 report differences between 10.5 dpc and 16.5 dpc. We found that the phenotypes of
528 OVA+ myometrial innate immune cells differed between 10.5 dpc and 16.5 dpc (Fig.
529 S4B-K).

530 Together, these data show that fetal antigen-carrying Ly6G+ cells (i.e.
531 neutrophils) and F4/80+ cells (i.e. monocytes) display unique phenotypes in the
532 maternal circulation.

533

534 **Fetal antigen-carrying Ly6G+OVA+ and F4/80+OVA+ cells display a** 535 **homeostatic cytokine profile in the maternal circulation**

536 Next, we investigated the expression of pro-inflammatory (IFN γ and TNF α)
537 and anti-inflammatory (IL-10 and TGF β) cytokines by Ly6G+OVA+ or Ly6G+OVA-
538 cells and F4/80+OVA+ or F4/80+OVA- cells. Maternal peripheral blood was collected
539 at 10.5 dpc or 16.5 dpc from wild type BALB/c females mated with B6 CAG-OVA
540 males, and immunophenotyping of OVA+ and OVA- neutrophils and monocytes was
541 performed (Fig. 5A). The expression of IFN γ by Ly6G+OVA+ cells was significantly
542 decreased compared to that of Ly6G+OVA- cells at 10.5 dpc and 16.5 dpc (Fig. 5B).
543 Similarly, the expression of TNF α by Ly6G+OVA+ cells was reduced compared to
544 that of Ly6G+OVA- cells at 10.5 dpc and 16.5 dpc; yet, significance was only

545 reached at 10.5 dpc (Fig. 5C). No significant differences in the expression of IL-10
546 and TGF β were observed between Ly6G+OVA+ and Ly6G+OVA- cells (Fig. 5D &
547 E). Although the expression of IFN γ and TNF α was similar between F4/80+OVA+
548 and F4/80+OVA- cells (Fig. 5F & G), the expression of IL-10 by F4/80+OVA+ cells
549 was greater than that of F4/80+OVA- cells at 10.5 dpc and 16.5 dpc; yet, significance
550 was only reached at 16.5 dpc (Fig. 5H). Interestingly, the expression of TGF β by
551 F4/80+OVA+ cells was greater than that of F4/80+OVA- cells at both 10.5 dpc and
552 16.5 dpc (Fig. 5I).

553 We also performed immunophenotyping of myometrial Ly6G+OVA+ and
554 F4/80+OVA+ cells to measure expression of cytokines that were determined in
555 OVA+ immune cells in the maternal circulation (Fig. S4A). We report that cytokine
556 expression by OVA+ myometrial innate immune cells partially differed between 10.5
557 dpc and 16.5 dpc (Fig. S4L-S).

558 Collectively, these results suggest that fetal antigen-carrying Ly6G+ cells (i.e.
559 neutrophils) and F4/80+ cells (i.e. monocytes) exhibit homeostatic functions in the
560 maternal circulation by expressing low levels of pro-inflammatory cytokines or
561 increased levels of anti-inflammatory cytokines, respectively.

562

563 **Maternal circulating Ly6G+ and F4/80+ cells phagocytose placenta-derived**

564 **particles in murine pregnancy**

565 Up to this point, our results suggest that maternal innate immune cells capture
566 the fetal antigen present in the maternal circulation. Therefore, we next investigated
567 whether particles derived from GFP+ placentas of allogeneic pregnancies were
568 phagocytosed by maternal peripheral Ly6G+ cells and F4/80+ cells from wild type
569 BALB/c dams mated with B6 CAG-OVA males (Fig. 6A). Flow cytometry was utilized

570 to determine the phagocytosis of GFP+ placental particles (Fig. 6B). Both maternal
571 Ly6G+ and F4/80+ cells were capable of phagocytosing placenta-derived particles at
572 10.5 dpc and 16.5 dpc (Fig. 6C & D). Consistent with the similar proportions of
573 Ly6G+OVA+ and F4/80+OVA+ cells observed between 10.5 dpc and 16.5 dpc, the
574 proportion of phagocytosis did not differ between these gestational time points for
575 either cell type (Fig. 6C & D). As expected, Ly6G+ and F4/80+ cells phagocytosed *E.*
576 *coli* efficiently, which served as a positive control for phagocytosis, and again no
577 differences were observed between 10.5 dpc and 16.5 dpc (Fig. S5A-D).
578 Immunofluorescence illustrated the uptake of placenta-derived particles by maternal
579 peripheral myeloid cells (CD11b+ cells) (Fig. 6E). These data offer functional
580 evidence that maternal circulating Ly6G+ cells (i.e. neutrophils) and F4/80+ cells (i.e.
581 monocytes) can phagocytose placenta-derived particles during mid and late murine
582 gestation.

583

584 **Maternal circulating CD15+ cells and CD14+ cells phagocytose** 585 **cytotrophoblast-derived particles in human pregnancy**

586 Lastly, to demonstrate the translational value of our findings in mice, we
587 performed *in vitro* studies using maternal peripheral CD15+ (i.e. neutrophils) and
588 CD14+ (i.e. monocytes) cells from second and third trimester pregnancies to explore
589 whether cytotrophoblast-derived particles can also be engulfed by such innate
590 immune cells (Fig. 7A). Particles were derived from Swan71 cytotrophoblast cells,
591 which have been conventionally utilized for the generation of exosomes for research
592 into maternal-fetal crosstalk [61, 104, 105]. Flow cytometry was utilized to determine
593 the phagocytosis of DiO-labelled cytotrophoblast-derived particles (Fig. 7B).
594 Consistent with our findings in mice, maternal CD15+ and CD14+ cells

595 phagocytosed cytotrophoblast-derived particles during the second and third trimester
596 (Fig. 7C & D). Such phagocytic activity appeared to be greater in the third trimester
597 compared to the second, but this increase did not reach statistical significance (Fig.
598 7C & D). Immunofluorescence imaging further demonstrated the uptake of
599 cytotrophoblast-derived particles by maternal phagocytes (Fig. 7E & F). As expected,
600 maternal CD15+ neutrophils and CD14+ monocytes also efficiently phagocytosed *E.*
601 *coli* (Fig. S5E-I). These findings provide translational value to our observations in
602 mice by demonstrating that maternal CD15+ cells (neutrophils) and CD14+ cells
603 (monocytes) are capable of capturing fetus-derived antigens in the maternal
604 circulation during the second and third trimester.

Author Manuscript

605 DISCUSSION

606 The immune mechanisms implicated in maternal-fetal crosstalk have been
607 extensively investigated in the uterine decidua, given that this is the primary site of
608 interaction between the mother and the developing fetus [1-3, 5]. Another
609 established site of maternal-fetal interaction is the intervillous space, which has
610 primarily been studied in the context of *in utero* transmission of pathogens [106-110]
611 and trans-placental transfer of antibodies [111-115]. Fetal antigens can also be
612 found in the maternal circulation [17, 44, 45, 116-119], where their concentrations
613 increase as gestation progresses [46, 85, 120-124]; however, their fate is largely
614 unknown. Herein, we provide evidence that fetal antigens can be encountered by
615 neutrophils and monocytes in the maternal circulation.

616 Neutrophils are the dominant immune cell type in the circulation and therefore
617 play a central role in host responses in both humans and mice. Pregnant women
618 display greater numbers of neutrophils in the circulation compared to non-pregnant
619 women [125-128], a phenomenon that is also observed in mice [129, 130]. Yet,
620 neutrophil numbers also vary throughout gestation [125]. A recent high-dimensional
621 study confirmed the cellular dynamics of circulating neutrophils during normal
622 gestation, and provided evidence of the responsiveness of these innate immune
623 cells to a variety of stimuli [131]. Indeed, neutrophils from pregnant women possess
624 a distinct phenotype from that of non-pregnant women, which is characterized by the
625 enhanced expression of activation markers such as CD14 and CD64 [69, 70].
626 Importantly, neutrophil responsiveness towards chemotactic agents (i.e. evidence of
627 leukocyte activation), including those derived from reproductive tissues, is increased
628 as gestation progresses and may serve as a biomarker for pregnancy complications
629 [71, 132-135]. Consistently, neutrophil effector functions such as ROS production

630 [69, 70, 72] and neutrophil extracellular trap (NET) formation [136] are boosted in
631 pregnancy compared to the non-pregnant state. Regarding phagocytosis, one of the
632 main functions of neutrophils, conflicting reports have suggested that this capability
633 may be diminished or improved in pregnancy [74-76]. In the current study, we
634 discovered that maternal neutrophils can phagocytose fetal antigens derived from
635 the placenta throughout gestation. To our knowledge, this is the first demonstration
636 that such a process occurs in the maternal circulation, providing evidence that
637 neutrophils participate in systemic maternal-fetal crosstalk.

638 Fetal antigen-carrying neutrophils displayed a unique phenotype
639 characterized by the upregulation of MHC-II and CD80, suggesting that these
640 maternal innate immune cells exhibit APC-like functions. Previous reports have
641 shown that non-pregnant adult neutrophils are capable of antigen presentation due
642 to their ability to phagocytose antigens and express APC markers such as MHC-II,
643 CD80, and CD86 [137-139]. However, dendritic cells and monocytes are superior to
644 neutrophils in their capacity for antigen presentation [140]. Our study also
645 demonstrated decreased expression of the pro-inflammatory cytokines IFN γ and
646 TNF α by fetal antigen-carrying neutrophils in the maternal circulation. These data
647 imply that, during pregnancy, circulating neutrophils exhibit anti-inflammatory
648 functions, a phenotype that has been termed "N2" [141-143]. These results are in
649 tandem with a previous report showing that neutrophils can exhibit homeostatic
650 functions during mid pregnancy [144]. Yet, additional research is required to explore
651 the contribution of neutrophils to fetal antigen presentation and tolerogenic
652 processes in the maternal circulation.

653 Monocytes represent the primary subset of circulating mononuclear cells and
654 carry out two essential functions: i) to act as sentinels in the blood vessels, and ii) to

655 transmigrate across the vessel endothelium to respond to tissue-derived signals or
656 threats [145]. Several reports have indicated that, similar to neutrophils, circulating
657 monocyte numbers increase throughout pregnancy [78, 126, 127, 146], although this
658 is not consistently observed [77]. Peripheral monocytes display a gradually
659 enhanced state of activation as gestation progresses [77, 147], indicated by elevated
660 cytokine responses [56, 79] and phosphorylation of key signaling molecules (e.g.
661 NF- κ B) [147]. Moreover, pregnancy-derived circulating monocytes display
662 upregulated expression of multiple activation markers such as CD11b, CD14, and
663 CD64 [69, 70, 77, 78]. Indeed, we have recently reported that single-cell RNA
664 sequencing-derived signatures from monocytes and macrophages are modulated in
665 the maternal circulation throughout gestation, and such signatures are increased in
666 women who underwent preterm labor and birth, providing a potential non-invasive
667 biomarker for the pathological process of labor [148]. Consistent with studies of
668 peripheral neutrophils, pregnancy has been separately reported to be associated
669 with decreased or enhanced phagocytic function by circulating monocytes [75, 80].
670 Herein, we observed that peripheral monocytes are capable of engulfing placenta-
671 derived antigens, establishing a potential mechanism whereby these innate immune
672 cells can participate in systemic maternal-fetal interactions.

673 Fetal antigen-carrying monocytes exhibited a homeostatic phenotype
674 characterized by the upregulation of CD86 together with an increased expression of
675 TGF β and IL-10. These findings are consistent with previous reports showing that
676 monocytes/macrophages exhibit immunoregulatory functions during pregnancy [30,
677 149, 150]. Specifically, uterine macrophage populations display an alternatively
678 activated phenotype and are involved in embryo implantation and placental
679 development as well as in host defense [33-35, 151-154]. Yet, monocytes in the

680 maternal circulation are less characterized, and we are currently engaged in the
681 investigation of their role during the second half of pregnancy. The systemic
682 depletion of monocytes/macrophages induces preterm labor and birth, highlighting
683 the homeostatic functions of these cells during pregnancy [155]. Consistently, the
684 adoptive transfer of M2-polarized (i.e. homeostatic) macrophages prevents preterm
685 birth in animal models of intra-amniotic inflammation [155-157]. Collectively, these
686 data suggest that maternal peripheral monocytes display homeostatic functions
687 during pregnancy, which include the uptake of fetal antigens released by the
688 placenta.

689 It is worth mentioning that fetal antigen-carrying neutrophils and monocytes
690 were also detected in the postpartum period (i.e. 48 - 60 hours after delivery), and
691 such cells may continue to decline as time progresses. Yet, the presence of these
692 cells may contribute to immunological memory [25, 26, 158-160].

693 A central question derived from our study concerns the events initiated in
694 maternal neutrophils and monocytes upon fetal antigen uptake. One possibility is
695 that maternal circulating innate immune cells phagocytose the fetal antigen for
696 containment to prevent aberrant antigen-specific T-cell responses that could
697 jeopardize pregnancy homeostasis. Another possibility is that maternal neutrophils
698 and monocytes internalize the fetal antigen for processing and transport to the
699 uterine draining lymph nodes to be presented by professional APCs, as has been
700 previously proposed [145, 161-163], where indirect antigen presentation occurs [81].
701 A third possibility is that the fetal antigen is processed and presented by maternal
702 neutrophils and monocytes to either circulating T cells or those in the lymphatic or
703 decidual tissues. However, each of the above hypotheses require mechanistic

704 investigation to ascertain the fate of the fetal antigen in the maternal circulation and
705 how this process contributes to the mechanisms of maternal-fetal tolerance.

706 The current study has some limitations. The sole use of the F4/80 marker
707 does not allow us to distinguish between monocytes and macrophages; yet, it can be
708 reasonably presumed that the majority of circulating maternal OVA+ cells represent
709 monocytes, whereas those in the myometrium are primarily tissue-resident
710 macrophages. In addition, the characterization of the placenta-derived particles used
711 in the current study, as well as the mechanisms whereby these particles are
712 engulfed by maternal phagocytes, warrants further investigation in future studies.
713 Lastly, functional characterization of those maternal innate immune cells that are
714 capable of engulfing fetal antigens is required.

715 In summary, herein we provide evidence that specific maternal innate immune
716 cells are capable of fetal antigen uptake and that such cells are most prevalent in the
717 second half of murine pregnancy. These innate immune cells displayed unique
718 phenotypes: while neutrophils expressed high levels of MHC-II and CD80 together
719 with low levels of pro-inflammatory cytokines, monocytes upregulated the expression
720 of CD86 as well as the anti-inflammatory cytokines IL-10 and TGF β . Importantly,
721 fetal antigen uptake was also displayed by neutrophils and monocytes from pregnant
722 women, providing translational evidence that this process also occurs in humans.
723 Collectively, these findings demonstrate novel interactions between specific maternal
724 circulating innate immune cells and fetal antigens, thereby shedding light on the
725 systemic mechanisms of maternal-fetal crosstalk.

726 **AUTHORSHIP**

727 M.A-H.: Investigation - Experimental Performance, Data Analysis, Writing – Original
728 Draft, Writing – Review, Editing, and Revision.

729 R. R.: Investigation - Study Design & Data interpretation, Writing – Review, Editing,
730 and Revision

731 M.G.: Investigation - Experimental Performance & Data Interpretation, Writing –
732 Original Draft, Writing – Review, Editing, and Revision

733 L.T., Y.X., V.G-F., E.P., G.S., and R.P.: Investigation - Experimental Performance,
734 Writing – Review, Editing, and Revision

735 D.M., J.G., and K.M.: Investigation, Writing – Original Draft, Writing – Review,
736 Editing, and Revision

737 N.G-L.: Conceptualization, Investigation – Study Design, Writing – Original Draft,
738 Writing – Review, Editing, and Revision

Author Manuscript

739 **ACKNOWLEDGEMENTS**

740 This research was supported by the Wayne State University Perinatal
741 Initiative in Maternal, Perinatal and Child Health. This research was also supported,
742 in part, by the Perinatology Research Branch, Division of Obstetrics and Maternal-
743 Fetal Medicine, Division of Intramural Research, *Eunice Kennedy Shriver* National
744 Institute of Child Health and Human Development, National Institutes of Health, U.S.
745 Department of Health and Human Services (NICHD/NIH/DHHS); and, in part, with
746 Federal funds from NICHD/NIH/DHHS under Contract No. HHSN275201300006C.
747 The authors would like to thank Chengrui Zou and Gregorio Martinez for their
748 assistance in carrying out some of the immunophenotyping and imaging
749 experiments.

750 Dr. Romero has contributed to this work as part of his official duties as an
751 employee of the United States Federal Government.

752 **CONFLICT OF INTEREST**

753 The authors declare no competing interests.

Author Manuscript

754 **REFERENCES**

- 755 1. Croy, B. A. and Murphy, S. P. Maternal-fetal immunology. *Immunol Invest*
756 2008; 37:389-394.
- 757 2. Chaouat, G., Petitbarat, M., Dubanchet, S., Rahmati, M., Ledee, N. Tolerance
758 to the foetal allograft? *Am J Reprod Immunol* 2010; 63:624-636.
- 759 3. Arck, P. C. and Hecher, K. Fetomaternal immune cross-talk and its
760 consequences for maternal and offspring's health. *Nat Med* 2013; 19:548-556.
- 761 4. Erlebacher, A. Immunology of the maternal-fetal interface. *Annu Rev Immunol*
762 2013; 31:387-411.
- 763 5. Bonney, E. A. Alternative theories: Pregnancy and immune tolerance. *J*
764 *Reprod Immunol* 2017; 123:65-71.
- 765 6. Petroff, M. G. Immune interactions at the maternal-fetal interface. *J Reprod*
766 *Immunol* 2005; 68:1-13.
- 767 7. Robertson, S. A., Guerin, L. R., Bromfield, J. J., Branson, K. M., Ahlstrom, A.
768 C., Care, A. S. Seminal fluid drives expansion of the CD4+CD25+ T
769 regulatory cell pool and induces tolerance to paternal alloantigens in mice.
770 *Biol Reprod* 2009; 80:1036-1045.
- 771 8. Robertson, S. A., Guerin, L. R., Moldenhauer, L. M., Hayball, J. D. Activating
772 T regulatory cells for tolerance in early pregnancy - the contribution of seminal
773 fluid. *J Reprod Immunol* 2009; 83:109-116.
- 774 9. Moldenhauer, L. M., Diener, K. R., Thring, D. M., Brown, M. P., Hayball, J. D.,
775 Robertson, S. A. Cross-presentation of male seminal fluid antigens elicits T
776 cell activation to initiate the female immune response to pregnancy. *J*
777 *Immunol* 2009; 182:8080-8093.

- 778 10. Guerin, L. R., Moldenhauer, L. M., Prins, J. R., Bromfield, J. J., Hayball, J. D.,
779 Robertson, S. A. Seminal fluid regulates accumulation of FOXP3+ regulatory
780 T cells in the preimplantation mouse uterus through expanding the FOXP3+
781 cell pool and CCL19-mediated recruitment. *Biol Reprod* 2011; 85:397-408.
- 782 11. Sharkey, D. J., Tremellen, K. P., Jasper, M. J., Gemzell-Danielsson, K.,
783 Robertson, S. A. Seminal fluid induces leukocyte recruitment and cytokine
784 and chemokine mRNA expression in the human cervix after coitus. *J Immunol*
785 2012; 188:2445-2454.
- 786 12. Saito, S., Shima, T., Nakashima, A., Inada, K., Yoshino, O. Role of Paternal
787 Antigen-Specific Treg Cells in Successful Implantation. *Am J Reprod Immunol*
788 2016; 75:310-316.
- 789 13. Moldenhauer, L. M., Schjenken, J. E., Hope, C. M., Green, E. S., Zhang, B.,
790 Eldi, P., Hayball, J. D., Barry, S. C., Robertson, S. A. Thymus-Derived
791 Regulatory T Cells Exhibit Foxp3 Epigenetic Modification and Phenotype
792 Attenuation after Mating in Mice. *J Immunol* 2019; 203:647-657.
- 793 14. Shima, T., Nakashima, A., Yasuda, I., Ushijima, A., Inada, K., Tsuda, S.,
794 Yoshino, O., Tomura, M., Saito, S. Uterine CD11c+ cells induce the
795 development of paternal antigen-specific Tregs via seminal plasma priming. *J*
796 *Reprod Immunol* 2020:103165.
- 797 15. Hill, J. A. Immunological mechanisms of pregnancy maintenance and failure:
798 a critique of theories and therapy. *Am J Reprod Immunol* 1990; 22:33-41.
- 799 16. Tafuri, A., Alferink, J., Moller, P., Hammerling, G. J., Arnold, B. T cell
800 awareness of paternal alloantigens during pregnancy. *Science* 1995; 270:630-
801 633.

- 802 17. Petroff, M. G. Review: Fetal antigens--identity, origins, and influences on the
803 maternal immune system. *Placenta* 2011; 32 Suppl 2:S176-181.
- 804 18. Chaouat, G., Voisin, G. A., Escalier, D., Robert, P. Facilitation reaction
805 (enhancing antibodies and suppressor cells) and rejection reaction (sensitized
806 cells) from the mother to the paternal antigens of the conceptus. *Clin Exp*
807 *Immunol* 1979; 35:13-24.
- 808 19. Aluvihare, V. R., Kallikourdis, M., Betz, A. G. Regulatory T cells mediate
809 maternal tolerance to the fetus. *Nat Immunol* 2004; 5:266-271.
- 810 20. Sasaki, Y., Sakai, M., Miyazaki, S., Higuma, S., Shiozaki, A., Saito, S.
811 Decidual and peripheral blood CD4+CD25+ regulatory T cells in early
812 pregnancy subjects and spontaneous abortion cases. *Mol Hum Reprod* 2004;
813 10:347-353.
- 814 21. Heikkinen, J., Mottonen, M., Alanen, A., Lassila, O. Phenotypic
815 characterization of regulatory T cells in the human decidua. *Clin Exp Immunol*
816 2004; 136:373-378.
- 817 22. Zenclussen, A. C., Gerlof, K., Zenclussen, M. L., Sollwedel, A., Bertoja, A. Z.,
818 Ritter, T., Kotsch, K., Leber, J., Volk, H. D. Abnormal T-cell reactivity against
819 paternal antigens in spontaneous abortion: adoptive transfer of pregnancy-
820 induced CD4+CD25+ T regulatory cells prevents fetal rejection in a murine
821 abortion model. *Am J Pathol* 2005; 166:811-822.
- 822 23. Kahn, D. A. and Baltimore, D. Pregnancy induces a fetal antigen-specific
823 maternal T regulatory cell response that contributes to tolerance. *Proc Natl*
824 *Acad Sci U S A* 2010; 107:9299-9304.
- 825 24. Shima, T., Sasaki, Y., Itoh, M., Nakashima, A., Ishii, N., Sugamura, K., Saito,
826 S. Regulatory T cells are necessary for implantation and maintenance of early

- 827 pregnancy but not late pregnancy in allogeneic mice. *J Reprod Immunol* 2010;
828 85:121-129.
- 829 25. Samstein, R. M., Josefowicz, S. Z., Arvey, A., Treuting, P. M., Rudensky, A.
830 Y. Extrathymic generation of regulatory T cells in placental mammals
831 mitigates maternal-fetal conflict. *Cell* 2012; 150:29-38.
- 832 26. Rowe, J. H., Ertelt, J. M., Xin, L., Way, S. S. Pregnancy imprints regulatory
833 memory that sustains anergy to fetal antigen. *Nature* 2012; 490:102-106.
- 834 27. Shima, T., Inada, K., Nakashima, A., Ushijima, A., Ito, M., Yoshino, O., Saito,
835 S. Paternal antigen-specific proliferating regulatory T cells are increased in
836 uterine-draining lymph nodes just before implantation and in pregnant uterus
837 just after implantation by seminal plasma-priming in allogeneic mouse
838 pregnancy. *J Reprod Immunol* 2015; 108:72-82.
- 839 28. van der Zwan, A., Bi, K., Norwitz, E. R., Crespo, A. C., Claas, F. H. J.,
840 Strominger, J. L., Tilburgs, T. Mixed signature of activation and dysfunction
841 allows human decidual CD8(+) T cells to provide both tolerance and immunity.
842 *Proc Natl Acad Sci U S A* 2018; 115:385-390.
- 843 29. Slutsky, R., Romero, R., Xu, Y., Galaz, J., Miller, D., Done, B., Tarca, A. L.,
844 Gregor, S., Hassan, S. S., Leng, Y., Gomez-Lopez, N. Exhausted and
845 Senescent T Cells at the Maternal-Fetal Interface in Preterm and Term Labor.
846 *J Immunol Res* 2019; 2019:3128010.
- 847 30. Hunt, J. S., Manning, L. S., Wood, G. W. Macrophages in murine uterus are
848 immunosuppressive. *Cell Immunol* 1984; 85:499-510.
- 849 31. Tawfik, O. W., Hunt, J. S., Wood, G. W. Partial characterization of uterine
850 cells responsible for suppression of murine maternal anti-fetal immune
851 responses. *J Reprod Immunol* 1986; 9:213-224.

- 852 32. Gustafsson, C., Mjosberg, J., Matussek, A., Geffers, R., Matthiesen, L., Berg,
853 G., Sharma, S., Buer, J., Ernerudh, J. Gene expression profiling of human
854 decidual macrophages: evidence for immunosuppressive phenotype. *PLoS*
855 *One* 2008; 3:e2078.
- 856 33. Repnik, U., Tilburgs, T., Roelen, D. L., van der Mast, B. J., Kanhai, H. H.,
857 Scherjon, S., Claas, F. H. Comparison of macrophage phenotype between
858 decidua basalis and decidua parietalis by flow cytometry. *Placenta* 2008;
859 29:405-412.
- 860 34. Svensson, J., Jenmalm, M. C., Matussek, A., Geffers, R., Berg, G., Ernerudh,
861 J. Macrophages at the fetal-maternal interface express markers of alternative
862 activation and are induced by M-CSF and IL-10. *J Immunol* 2011; 187:3671-
863 3682.
- 864 35. Houser, B. L., Tilburgs, T., Hill, J., Nicotra, M. L., Strominger, J. L. Two unique
865 human decidual macrophage populations. *J Immunol* 2011; 186:2633-2642.
- 866 36. Miller, D., Motomura, K., Garcia-Flores, V., Romero, R., Gomez-Lopez, N.
867 Innate Lymphoid Cells in the Maternal and Fetal Compartments. *Front*
868 *Immunol* 2018; 9:2396.
- 869 37. Mendes, J., Areia, A. L., Rodrigues-Santos, P., Santos-Rosa, M., Mota-Pinto,
870 A. Innate Lymphoid Cells in Human Pregnancy. *Front Immunol* 2020;
871 11:551707.
- 872 38. Ellis, S. A., Sargent, I. L., Redman, C. W., McMichael, A. J. Evidence for a
873 novel HLA antigen found on human extravillous trophoblast and a
874 choriocarcinoma cell line. *Immunology* 1986; 59:595-601.

- 875 39. Kovats, S., Main, E. K., Librach, C., Stubblebine, M., Fisher, S. J., DeMars, R.
876 A class I antigen, HLA-G, expressed in human trophoblasts. *Science* 1990;
877 248:220-223.
- 878 40. Chumbley, G., King, A., Robertson, K., Holmes, N., Loke, Y. W. Resistance of
879 HLA-G and HLA-A2 transfectants to lysis by decidual NK cells. *Cell Immunol*
880 1994; 155:312-322.
- 881 41. Vento-Tormo, R., Efremova, M., Botting, R. A., Turco, M. Y., Vento-Tormo,
882 M., Meyer, K. B., Park, J. E., Stephenson, E., Polanski, K., Goncalves, A.,
883 Gardner, L., Holmqvist, S., Henriksson, J., Zou, A., Sharkey, A. M., Millar, B.,
884 Innes, B., Wood, L., Wilbrey-Clark, A., Payne, R. P., Ivarsson, M. A., Lisgo,
885 S., Filby, A., Rowitch, D. H., Bulmer, J. N., Wright, G. J., Stubbington, M. J. T.,
886 Haniffa, M., Moffett, A., Teichmann, S. A. Single-cell reconstruction of the
887 early maternal-fetal interface in humans. *Nature* 2018; 563:347-353.
- 888 42. Zhang, Y. H., Aldo, P., You, Y., Ding, J., Kaislasuo, J., Petersen, J. F.,
889 Lokkegaard, E., Peng, G., Paidas, M. J., Simpson, S., Pal, L., Guller, S., Liu,
890 H., Liao, A. H., Mor, G. Trophoblast-secreted soluble-PD-L1 modulates
891 macrophage polarization and function. *J Leukoc Biol* 2020; 108:983-998.
- 892 43. PrabhuDas, M., Bonney, E., Caron, K., Dey, S., Erlebacher, A., Fazleabas, A.,
893 Fisher, S., Golos, T., Matzuk, M., McCune, J. M., Mor, G., Schulz, L., Soares,
894 M., Spencer, T., Strominger, J., Way, S. S., Yoshinaga, K. Immune
895 mechanisms at the maternal-fetal interface: perspectives and challenges. *Nat*
896 *Immunol* 2015; 16:328-334.
- 897 44. Herzenberg, L. A., Bianchi, D. W., Schroder, J., Cann, H. M., Iverson, G. M.
898 Fetal cells in the blood of pregnant women: detection and enrichment by

- 899 fluorescence-activated cell sorting. *Proc Natl Acad Sci U S A* 1979; 76:1453-
900 1455.
- 901 45. Bianchi, D. W., Zickwolf, G. K., Weil, G. J., Sylvester, S., DeMaria, M. A. Male
902 fetal progenitor cells persist in maternal blood for as long as 27 years
903 postpartum. *Proc Natl Acad Sci U S A* 1996; 93:705-708.
- 904 46. Ariga, H., Ohto, H., Busch, M. P., Imamura, S., Watson, R., Reed, W., Lee, T.
905 H. Kinetics of fetal cellular and cell-free DNA in the maternal circulation during
906 and after pregnancy: implications for noninvasive prenatal diagnosis.
907 *Transfusion* 2001; 41:1524-1530.
- 908 47. Maloney, S., Smith, A., Furst, D. E., Myerson, D., Rupert, K., Evans, P. C.,
909 Nelson, J. L. Microchimerism of maternal origin persists into adult life. *J Clin*
910 *Invest* 1999; 104:41-47.
- 911 48. Srivatsa, B., Srivatsa, S., Johnson, K. L., Bianchi, D. W. Maternal cell
912 microchimerism in newborn tissues. *J Pediatr* 2003; 142:31-35.
- 913 49. Su, E. C., Johnson, K. L., Tighiouart, H., Bianchi, D. W. Murine maternal cell
914 microchimerism: analysis using real-time PCR and in vivo imaging. *Biol*
915 *Reprod* 2008; 78:883-887.
- 916 50. Stevens, A. M., Hermes, H. M., Kiefer, M. M., Rutledge, J. C., Nelson, J. L.
917 Chimeric maternal cells with tissue-specific antigen expression and
918 morphology are common in infant tissues. *Pediatr Dev Pathol* 2009; 12:337-
919 346.
- 920 51. Kinder, J. M., Stelzer, I. A., Arck, P. C., Way, S. S. Immunological implications
921 of pregnancy-induced microchimerism. *Nat Rev Immunol* 2017; 17:483-494.

- 922 52. Cheng, S. B., Davis, S., Sharma, S. Maternal-fetal cross talk through cell-free
923 fetal DNA, telomere shortening, microchimerism, and inflammation. *Am J*
924 *Reprod Immunol* 2018; 79:e12851.
- 925 53. Knight, M., Redman, C. W., Linton, E. A., Sargent, I. L. Shedding of
926 syncytiotrophoblast microvilli into the maternal circulation in pre-eclamptic
927 pregnancies. *Br J Obstet Gynaecol* 1998; 105:632-640.
- 928 54. Sabapatha, A., Gercel-Taylor, C., Taylor, D. D. Specific isolation of placenta-
929 derived exosomes from the circulation of pregnant women and their
930 immunoregulatory consequences. *Am J Reprod Immunol* 2006; 56:345-355.
- 931 55. Redman, C. W. and Sargent, I. L. Microparticles and immunomodulation in
932 pregnancy and pre-eclampsia. *J Reprod Immunol* 2007; 76:61-67.
- 933 56. Germain, S. J., Sacks, G. P., Sooranna, S. R., Sargent, I. L., Redman, C. W.
934 Systemic inflammatory priming in normal pregnancy and preeclampsia: the
935 role of circulating syncytiotrophoblast microparticles. *J Immunol* 2007;
936 178:5949-5956.
- 937 57. Burton, G. J. and Jones, C. J. Syncytial knots, sprouts, apoptosis, and
938 trophoblast deportation from the human placenta. *Taiwan J Obstet Gynecol*
939 2009; 48:28-37.
- 940 58. Holland, O. J., Linscheid, C., Hodes, H. C., Nauser, T. L., Gilliam, M., Stone,
941 P., Chamley, L. W., Petroff, M. G. Minor histocompatibility antigens are
942 expressed in syncytiotrophoblast and trophoblast debris: implications for
943 maternal alloreactivity to the fetus. *Am J Pathol* 2012; 180:256-266.
- 944 59. Stenqvist, A. C., Nagaeva, O., Baranov, V., Mincheva-Nilsson, L. Exosomes
945 secreted by human placenta carry functional Fas ligand and TRAIL molecules

- 946 and convey apoptosis in activated immune cells, suggesting exosome-
947 mediated immune privilege of the fetus. *J Immunol* 2013; 191:5515-5523.
- 948 60. Gohner, C., Plosch, T., Faas, M. M. Immune-modulatory effects of
949 syncytiotrophoblast extracellular vesicles in pregnancy and preeclampsia.
950 *Placenta* 2017; 60 Suppl 1:S41-S51.
- 951 61. Familiar, M., Cronqvist, T., Masoumi, Z., Hansson, S. R. Placenta-derived
952 extracellular vesicles: their cargo and possible functions. *Reprod Fertil Dev*
953 2017; 29:433-447.
- 954 62. Tong, M., Abrahams, V. M., Chamley, L. W. Immunological effects of
955 placental extracellular vesicles. *Immunol Cell Biol* 2018.
- 956 63. Nair, S. and Salomon, C. Extracellular vesicles and their immunomodulatory
957 functions in pregnancy. *Semin Immunopathol* 2018; 40:425-437.
- 958 64. Reddy, A., Zhong, X. Y., Rusterholz, C., Hahn, S., Holzgreve, W., Redman, C.
959 W., Sargent, I. L. The effect of labour and placental separation on the
960 shedding of syncytiotrophoblast microparticles, cell-free DNA and mRNA in
961 normal pregnancy and pre-eclampsia. *Placenta* 2008; 29:942-949.
- 962 65. Kshirsagar, S. K., Alam, S. M., Jasti, S., Hodes, H., Nauser, T., Gilliam, M.,
963 Billstrand, C., Hunt, J. S., Petroff, M. G. Immunomodulatory molecules are
964 released from the first trimester and term placenta via exosomes. *Placenta*
965 2012; 33:982-990.
- 966 66. Tannetta, D. S., Dragovic, R. A., Gardiner, C., Redman, C. W., Sargent, I. L.
967 Characterisation of syncytiotrophoblast vesicles in normal pregnancy and pre-
968 eclampsia: expression of Flt-1 and endoglin. *PLoS One* 2013; 8:e56754.

- 969 67. Kovacs, A. F., Fekete, N., Turiak, L., Acs, A., Kohidai, L., Buzas, E. I.,
970 Pallinger, E. Unravelling the Role of Trophoblastic-Derived Extracellular
971 Vesicles in Regulatory T Cell Differentiation. *Int J Mol Sci* 2019; 20.
- 972 68. Tannetta, D., Collett, G., Vatish, M., Redman, C., Sargent, I.
973 Syncytiotrophoblast extracellular vesicles - Circulating biopsies reflecting
974 placental health. *Placenta* 2017; 52:134-138.
- 975 69. Sacks, G. P., Studena, K., Sargent, K., Redman, C. W. Normal pregnancy
976 and preeclampsia both produce inflammatory changes in peripheral blood
977 leukocytes akin to those of sepsis. *Am J Obstet Gynecol* 1998; 179:80-86.
- 978 70. Naccasha, N., Gervasi, M. T., Chaiworapongsa, T., Berman, S., Yoon, B. H.,
979 Maymon, E., Romero, R. Phenotypic and metabolic characteristics of
980 monocytes and granulocytes in normal pregnancy and maternal infection. *Am*
981 *J Obstet Gynecol* 2001; 185:1118-1123.
- 982 71. Gomez-Lopez, N., Tanaka, S., Zaeem, Z., Metz, G. A., Olson, D. M. Maternal
983 circulating leukocytes display early chemotactic responsiveness during late
984 gestation. *BMC Pregnancy Childbirth* 2013; 13 Suppl 1:S8.
- 985 72. Kindzelskii, A. L., Ueki, T., Michibata, H., Chaiworapongsa, T., Romero, R.,
986 Petty, H. R. 6-phosphogluconate dehydrogenase and glucose-6-phosphate
987 dehydrogenase form a supramolecular complex in human neutrophils that
988 undergoes retrograde trafficking during pregnancy. *J Immunol* 2004;
989 172:6373-6381.
- 990 73. Kindzelskii, A. L., Clark, A. J., Espinoza, J., Maeda, N., Aratani, Y., Romero,
991 R., Petty, H. R. Myeloperoxidase accumulates at the neutrophil surface and
992 enhances cell metabolism and oxidant release during pregnancy. *Eur J*
993 *Immunol* 2006; 36:1619-1628.

- 994 74. Persellin, R. H. and Thoi, L. L. Human polymorphonuclear leukocyte
995 phagocytosis in pregnancy. Development of inhibition during gestation and
996 recovery in the postpartum period. *Am J Obstet Gynecol* 1979; 134:250-255.
- 997 75. Lampe, R., Kover, A., Szucs, S., Pal, L., Arnyas, E., Adany, R., Poka, R.
998 Phagocytic index of neutrophil granulocytes and monocytes in healthy and
999 preeclamptic pregnancy. *J Reprod Immunol* 2015; 107:26-30.
- 1000 76. Barriga, C., Rodriguez, A. B., Ortega, E. Increased phagocytic activity of
1001 polymorphonuclear leukocytes during pregnancy. *Eur J Obstet Gynecol*
1002 *Reprod Biol* 1994; 57:43-46.
- 1003 77. Luppi, P., Haluszczak, C., Betters, D., Richard, C. A., Trucco, M., DeLoia, J.
1004 A. Monocytes are progressively activated in the circulation of pregnant
1005 women. *J Leukoc Biol* 2002; 72:874-884.
- 1006 78. Pflitsch, C., Feldmann, C. N., Richert, L., Hagen, S., Diemert, A., Goletzke, J.,
1007 Hecher, K., Jazbutyte, V., Renne, T., Arck, P. C., Altfeld, M., Ziegler, S. In-
1008 depth characterization of monocyte subsets during the course of healthy
1009 pregnancy. *J Reprod Immunol* 2020; 141:103151.
- 1010 79. Sacks, G. P., Redman, C. W., Sargent, I. L. Monocytes are primed to produce
1011 the Th1 type cytokine IL-12 in normal human pregnancy: an intracellular flow
1012 cytometric analysis of peripheral blood mononuclear cells. *Clin Exp Immunol*
1013 2003; 131:490-497.
- 1014 80. Koumandakis, E., Koumandaki, I., Kaklamani, E., Sparos, L., Aravantinos, D.,
1015 Trichopoulos, D. Enhanced phagocytosis of mononuclear phagocytes in
1016 pregnancy. *Br J Obstet Gynaecol* 1986; 93:1150-1154.

- 1017 81. Erlebacher, A., Vencato, D., Price, K. A., Zhang, D., Glimcher, L. H.
1018 Constraints in antigen presentation severely restrict T cell recognition of the
1019 allogeneic fetus. *J Clin Invest* 2007; 117:1399-1411.
- 1020 82. Moldenhauer, L. M., Hayball, J. D., Robertson, S. A. Utilising T cell receptor
1021 transgenic mice to define mechanisms of maternal T cell tolerance in
1022 pregnancy. *J Reprod Immunol* 2010; 87:1-13.
- 1023 83. Petroff, M. G. Review: Fetal antigens--identity, origins, and influences on the
1024 maternal immune system. *Placenta* 2011; 32 Suppl 2:S176-181.
- 1025 84. Arenas-Hernandez, M., Sanchez-Rodriguez, E. N., Mial, T. N., Robertson, S.
1026 A., Gomez-Lopez, N. Isolation of Leukocytes from the Murine Tissues at the
1027 Maternal-Fetal Interface. *J Vis Exp* 2015:e52866.
- 1028 85. Gomez-Lopez, N., Romero, R., Schwenkel, G., Garcia-Flores, V., Panaitescu,
1029 B., Varrey, A., Ayoub, F., Hassan, S. S., Phillippe, M. Cell-Free Fetal DNA
1030 Increases Prior to Labor at Term and in a Subset of Preterm Births. *Reprod*
1031 *Sci* 2020; 27:218-232.
- 1032 86. Straszewski-Chavez, S. L., Abrahams, V. M., Alvero, A. B., Aldo, P. B., Ma,
1033 Y., Guller, S., Romero, R., Mor, G. The isolation and characterization of a
1034 novel telomerase immortalized first trimester trophoblast cell line, Swan 71.
1035 *Placenta* 2009; 30:939-948.
- 1036 87. Jain, C. V., Kadam, L., van Dijk, M., Kohan-Ghadr, H. R., Kilburn, B. A.,
1037 Hartman, C., Mazzorana, V., Visser, A., Hertz, M., Bolnick, A. D., Fritz, R.,
1038 Armant, D. R., Drewlo, S. Fetal genome profiling at 5 weeks of gestation after
1039 noninvasive isolation of trophoblast cells from the endocervical canal. *Sci*
1040 *Transl Med* 2016; 8:363re364.

- 1041 88. Moser, G., Drewlo, S., Huppertz, B., Armant, D. R. Trophoblast retrieval and
1042 isolation from the cervix: origins of cervical trophoblasts and their potential
1043 value for risk assessment of ongoing pregnancies. *Hum Reprod Update* 2018;
1044 24:484-496.
- 1045 89. Todd, R. F., 3rd, Nadler, L. M., Schlossman, S. F. Antigens on human
1046 monocytes identified by monoclonal antibodies. *J Immunol* 1981; 126:1435-
1047 1442.
- 1048 90. Chen, H. M., Pahl, H. L., Scheibe, R. J., Zhang, D. E., Tenen, D. G. The Sp1
1049 transcription factor binds the CD11b promoter specifically in myeloid cells in
1050 vivo and is essential for myeloid-specific promoter activity. *J Biol Chem* 1993;
1051 268:8230-8239.
- 1052 91. Gustafson, M. P., Lin, Y., Maas, M. L., Van Keulen, V. P., Johnston, P. B.,
1053 Peikert, T., Gastineau, D. A., Dietz, A. B. A method for identification and
1054 analysis of non-overlapping myeloid immunophenotypes in humans. *PLoS*
1055 *One* 2015; 10:e0121546.
- 1056 92. Rosen, H. and Gordon, S. Monoclonal antibody to the murine type 3
1057 complement receptor inhibits adhesion of myelomonocytic cells in vitro and
1058 inflammatory cell recruitment in vivo. *J Exp Med* 1987; 166:1685-1701.
- 1059 93. Jutila, M. A., Rott, L., Berg, E. L., Butcher, E. C. Function and regulation of the
1060 neutrophil MEL-14 antigen in vivo: comparison with LFA-1 and MAC-1. *J*
1061 *Immunol* 1989; 143:3318-3324.
- 1062 94. Roche, P. A. and Furuta, K. The ins and outs of MHC class II-mediated
1063 antigen processing and presentation. *Nat Rev Immunol* 2015; 15:203-216.
- 1064 95. Chen, L. and Flies, D. B. Molecular mechanisms of T cell co-stimulation and
1065 co-inhibition. *Nat Rev Immunol* 2013; 13:227-242.

- 1066 96. Ezekowitz, R. A., Sastry, K., Bailly, P., Warner, A. Molecular characterization
1067 of the human macrophage mannose receptor: demonstration of multiple
1068 carbohydrate recognition-like domains and phagocytosis of yeasts in Cos-1
1069 cells. *J Exp Med* 1990; 172:1785-1794.
- 1070 97. Cuartero, M. I., Ballesteros, I., Moraga, A., Nombela, F., Vivancos, J.,
1071 Hamilton, J. A., Corbi, A. L., Lizasoain, I., Moro, M. A. N2 neutrophils, novel
1072 players in brain inflammation after stroke: modulation by the PPARgamma
1073 agonist rosiglitazone. *Stroke* 2013; 44:3498-3508.
- 1074 98. Nielsen, M. C., Andersen, M. N., Rittig, N., Rodgaard-Hansen, S., Gronbaek,
1075 H., Moestrup, S. K., Moller, H. J., Etzerodt, A. The macrophage-related
1076 biomarkers sCD163 and sCD206 are released by different shedding
1077 mechanisms. *J Leukoc Biol* 2019; 106:1129-1138.
- 1078 99. Ono, Y., Yoshino, O., Hiraoka, T., Sato, E., Fukui, Y., Ushijima, A., Nawaz, A.,
1079 Hirota, Y., Wada, S., Tobe, K., Nakashima, A., Osuga, Y., Saito, S. CD206+
1080 M2-Like Macrophages Are Essential for Successful Implantation. *Front*
1081 *Immunol* 2020; 11:557184.
- 1082 100. Simon, S. I., Burns, A. R., Taylor, A. D., Gopalan, P. K., Lynam, E. B., Sklar,
1083 L. A., Smith, C. W. L-selectin (CD62L) cross-linking signals neutrophil
1084 adhesive functions via the Mac-1 (CD11b/CD18) beta 2-integrin. *J Immunol*
1085 1995; 155:1502-1514.
- 1086 101. Leon, B. and Ardavin, C. Monocyte migration to inflamed skin and lymph
1087 nodes is differentially controlled by L-selectin and PSGL-1. *Blood* 2008;
1088 111:3126-3130.
- 1089 102. Bjorkman, L., Christenson, K., Davidsson, L., Martensson, J., Amirbeagi, F.,
1090 Welin, A., Forsman, H., Karlsson, A., Dahlgren, C., Bylund, J. Neutrophil

- 1091 recruitment to inflamed joints can occur without cellular priming. *J Leukoc Biol*
1092 2019; 105:1123-1130.
- 1093 103. Chadwick, J. W., Fine, N., Khoury, W., Tasevski, N., Sun, C. X., Boroumand,
1094 P., Klip, A., Glogauer, M. Tissue-specific murine neutrophil activation states in
1095 health and inflammation. *J Leukoc Biol* 2020.
- 1096 104. Atay, S., Gercel-Taylor, C., Kesimer, M., Taylor, D. D. Morphologic and
1097 proteomic characterization of exosomes released by cultured extravillous
1098 trophoblast cells. *Exp Cell Res* 2011; 317:1192-1202.
- 1099 105. Alam, S. M. K., Jasti, S., Kshirsagar, S. K., Tannetta, D. S., Dragovic, R. A.,
1100 Redman, C. W., Sargent, I. L., Hodes, H. C., Nauser, T. L., Fortes, T., Filler,
1101 A. M., Behan, K., Martin, D. R., Fields, T. A., Petroff, B. K., Petroff, M. G.
1102 Trophoblast Glycoprotein (TPGB/5T4) in Human Placenta: Expression,
1103 Regulation, and Presence in Extracellular Microvesicles and Exosomes.
1104 *Reprod Sci* 2018; 25:185-197.
- 1105 106. Delorme-Axford, E., Donker, R. B., Mouillet, J. F., Chu, T., Bayer, A., Ouyang,
1106 Y., Wang, T., Stolz, D. B., Sarkar, S. N., Morelli, A. E., Sadovsky, Y., Coyne,
1107 C. B. Human placental trophoblasts confer viral resistance to recipient cells.
1108 *Proc Natl Acad Sci U S A* 2013; 110:12048-12053.
- 1109 107. Delorme-Axford, E., Bayer, A., Sadovsky, Y., Coyne, C. B. Autophagy as a
1110 mechanism of antiviral defense at the maternal-fetal interface. *Autophagy*
1111 2013; 9:2173-2174.
- 1112 108. Bayer, A., Lennemann, N. J., Ouyang, Y., Bramley, J. C., Morosky, S.,
1113 Marques, E. T., Jr., Cherry, S., Sadovsky, Y., Coyne, C. B. Type III Interferons
1114 Produced by Human Placental Trophoblasts Confer Protection against Zika
1115 Virus Infection. *Cell Host Microbe* 2016; 19:705-712.

- 1116 109. Arora, N., Sadovsky, Y., Dermody, T. S., Coyne, C. B. Microbial Vertical
1117 Transmission during Human Pregnancy. *Cell Host Microbe* 2017; 21:561-567.
- 1118 110. Megli, C., Morosky, S., Rajasundaram, D., Coyne, C. B. Inflammasome
1119 signaling in human placental trophoblasts regulates immune defense against
1120 *Listeria monocytogenes* infection. *J Exp Med* 2021; 218.
- 1121 111. Simister, N. E., Story, C. M., Chen, H. L., Hunt, J. S. An IgG-transporting Fc
1122 receptor expressed in the syncytiotrophoblast of human placenta. *Eur J*
1123 *Immunol* 1996; 26:1527-1531.
- 1124 112. Firan, M., Bawdon, R., Radu, C., Ober, R. J., Eaken, D., Antohe, F., Ghetie,
1125 V., Ward, E. S. The MHC class I-related receptor, FcRn, plays an essential
1126 role in the maternofetal transfer of gamma-globulin in humans. *Int Immunol*
1127 2001; 13:993-1002.
- 1128 113. Radulescu, L., Antohe, F., Jinga, V., Ghetie, V., Simionescu, M. Neonatal Fc
1129 receptors discriminates and monitors the pathway of native and modified
1130 immunoglobulin G in placental endothelial cells. *Hum Immunol* 2004; 65:578-
1131 585.
- 1132 114. Palmeira, P., Costa-Carvalho, B. T., Arslanian, C., Pontes, G. N., Nagao, A.
1133 T., Carneiro-Sampaio, M. M. Transfer of antibodies across the placenta and in
1134 breast milk from mothers on intravenous immunoglobulin. *Pediatr Allergy*
1135 *Immunol* 2009; 20:528-535.
- 1136 115. Palmeira, P., Quinello, C., Silveira-Lessa, A. L., Zago, C. A., Carneiro-
1137 Sampaio, M. IgG placental transfer in healthy and pathological pregnancies.
1138 *Clin Dev Immunol* 2012; 2012:985646.

- 1139 116. Lo, Y. M., Lo, E. S., Watson, N., Noakes, L., Sargent, I. L., Thilaganathan, B.,
1140 Wainscoat, J. S. Two-way cell traffic between mother and fetus: biologic and
1141 clinical implications. *Blood* 1996; 88:4390-4395.
- 1142 117. Lapaire, O., Holzgreve, W., Oosterwijk, J. C., Brinkhaus, R., Bianchi, D. W.
1143 Georg Schmorl on trophoblasts in the maternal circulation. *Placenta* 2007;
1144 28:1-5.
- 1145 118. Redman, C. W. and Sargent, I. L. Circulating microparticles in normal
1146 pregnancy and pre-eclampsia. *Placenta* 2008; 29 Suppl A:S73-77.
- 1147 119. Jeanty, C., Derderian, S. C., Mackenzie, T. C. Maternal-fetal cellular
1148 trafficking: clinical implications and consequences. *Curr Opin Pediatr* 2014;
1149 26:377-382.
- 1150 120. Lo, Y. M., Corbetta, N., Chamberlain, P. F., Rai, V., Sargent, I. L., Redman, C.
1151 W., Wainscoat, J. S. Presence of fetal DNA in maternal plasma and serum.
1152 *Lancet* 1997; 350:485-487.
- 1153 121. Lo, Y. M., Tein, M. S., Lau, T. K., Haines, C. J., Leung, T. N., Poon, P. M.,
1154 Wainscoat, J. S., Johnson, P. J., Chang, A. M., Hjelm, N. M. Quantitative
1155 analysis of fetal DNA in maternal plasma and serum: implications for
1156 noninvasive prenatal diagnosis. *Am J Hum Genet* 1998; 62:768-775.
- 1157 122. Khosrotehrani, K., Wataganara, T., Bianchi, D. W., Johnson, K. L. Fetal cell-
1158 free DNA circulates in the plasma of pregnant mice: relevance for animal
1159 models of fetomaternal trafficking. *Hum Reprod* 2004; 19:2460-2464.
- 1160 123. Taglauer, E. S., Wilkins-Haug, L., Bianchi, D. W. Review: cell-free fetal DNA
1161 in the maternal circulation as an indication of placental health and disease.
1162 *Placenta* 2014; 35 Suppl:S64-68.

- 1163 124. Herrera, C. A., Stoerker, J., Carlquist, J., Stoddard, G. J., Jackson, M., Esplin,
1164 S., Rose, N. C. Cell-free DNA, inflammation, and the initiation of spontaneous
1165 term labor. *Am J Obstet Gynecol* 2017; 217:583 e581-583 e588.
- 1166 125. Belo, L., Santos-Silva, A., Rocha, S., Caslake, M., Cooney, J., Pereira-Leite,
1167 L., Quintanilha, A., Rebelo, I. Fluctuations in C-reactive protein concentration
1168 and neutrophil activation during normal human pregnancy. *Eur J Obstet*
1169 *Gynecol Reprod Biol* 2005; 123:46-51.
- 1170 126. Veenstra van Nieuwenhoven, A. L., Bouman, A., Moes, H., Heineman, M. J.,
1171 de Leij, L. F., Santema, J., Faas, M. M. Endotoxin-induced cytokine
1172 production of monocytes of third-trimester pregnant women compared with
1173 women in the follicular phase of the menstrual cycle. *Am J Obstet Gynecol*
1174 2003; 188:1073-1077.
- 1175 127. Kraus, T. A., Engel, S. M., Sperling, R. S., Kellerman, L., Lo, Y., Wallenstein,
1176 S., Escribese, M. M., Garrido, J. L., Singh, T., Loubeau, M., Moran, T. M.
1177 Characterizing the pregnancy immune phenotype: results of the viral immunity
1178 and pregnancy (VIP) study. *J Clin Immunol* 2012; 32:300-311.
- 1179 128. Kostlin, N., Kugel, H., Spring, B., Leiber, A., Marme, A., Henes, M., Rieber,
1180 N., Hartl, D., Poets, C. F., Gille, C. Granulocytic myeloid derived suppressor
1181 cells expand in human pregnancy and modulate T-cell responses. *Eur J*
1182 *Immunol* 2014; 44:2582-2591.
- 1183 129. Pan, T., Liu, Y., Zhong, L. M., Shi, M. H., Duan, X. B., Wu, K., Yang, Q., Liu,
1184 C., Wei, J. Y., Ma, X. R., Shi, K., Zhang, H., Zhou, J. Myeloid-derived
1185 suppressor cells are essential for maintaining feto-maternal immunotolerance
1186 via STAT3 signaling in mice. *J Leukoc Biol* 2016; 100:499-511.

- 1187 130. Ostrand-Rosenberg, S., Sinha, P., Figley, C., Long, R., Park, D., Carter, D.,
1188 Clements, V. K. Frontline Science: Myeloid-derived suppressor cells (MDSCs)
1189 facilitate maternal-fetal tolerance in mice. *J Leukoc Biol* 2017; 101:1091-1101.
- 1190 131. Aghaeepour, N., Ganio, E. A., McIlwain, D., Tsai, A. S., Tingle, M., Van
1191 Gassen, S., Gaudilliere, D. K., Baca, Q., McNeil, L., Okada, R., Ghaemi, M.
1192 S., Furman, D., Wong, R. J., Winn, V. D., Druzin, M. L., El-Sayed, Y. Y.,
1193 Quaintance, C., Gibbs, R., Darmstadt, G. L., Shaw, G. M., Stevenson, D. K.,
1194 Tibshirani, R., Nolan, G. P., Lewis, D. B., Angst, M. S., Gaudilliere, B. An
1195 immune clock of human pregnancy. *Sci Immunol* 2017; 2.
- 1196 132. Gomez-Lopez, N., Laresgoiti-Servitje, E., Olson, D. M., Estrada-Gutierrez, G.,
1197 Vadillo-Ortega, F. The role of chemokines in term and premature rupture of
1198 the fetal membranes: a review. *Biol Reprod* 2010; 82:809-814.
- 1199 133. Gomez-Lopez, N., Vadillo-Perez, L., Nessim, S., Olson, D. M., Vadillo-Ortega,
1200 F. Choriondecidua and amnion exhibit selective leukocyte chemotaxis during
1201 term human labor. *Am J Obstet Gynecol* 2011; 204:364 e369-316.
- 1202 134. Gomez-Lopez, N. and Olson, D. (2012) Leukocyte activation and methods of
1203 use thereof. (USPTO, ed) The Governors of the University of Alberta, United
1204 States.
- 1205 135. Gomez-Lopez, N., Tong, W. C., Arenas-Hernandez, M., Tanaka, S., Hajar, O.,
1206 Olson, D. M., Taggart, M. J., Mitchell, B. F. Chemotactic activity of gestational
1207 tissues through late pregnancy, term labor, and RU486-induced preterm labor
1208 in Guinea pigs. *Am J Reprod Immunol* 2015; 73:341-352.
- 1209 136. Giaglis, S., Stoikou, M., Sur Chowdhury, C., Schaefer, G., Grimolizzi, F.,
1210 Rossi, S. W., Hoesli, I. M., Lapaire, O., Hasler, P., Hahn, S. Multimodal

- 1211 Regulation of NET Formation in Pregnancy: Progesterone Antagonizes the
1212 Pro-NETotic Effect of Estrogen and G-CSF. *Front Immunol* 2016; 7:565.
- 1213 137. Gosselin, E. J., Wardwell, K., Rigby, W. F., Guyre, P. M. Induction of MHC
1214 class II on human polymorphonuclear neutrophils by granulocyte/macrophage
1215 colony-stimulating factor, IFN-gamma, and IL-3. *J Immunol* 1993; 151:1482-
1216 1490.
- 1217 138. Windhagen, A., Maniak, S., Gebert, A., Ferger, I., Wurster, U., Heidenreich, F.
1218 Human polymorphonuclear neutrophils express a B7-1-like molecule. *J*
1219 *Leukoc Biol* 1999; 66:945-952.
- 1220 139. Meinderts, S. M., Baker, G., van Wijk, S., Beuger, B. M., Geissler, J., Jansen,
1221 M. H., Saris, A., Ten Brinke, A., Kuijpers, T. W., van den Berg, T. K., van
1222 Bruggen, R. Neutrophils acquire antigen-presenting cell features after
1223 phagocytosis of IgG-opsonized erythrocytes. *Blood Adv* 2019; 3:1761-1773.
- 1224 140. Vono, M., Lin, A., Norrby-Teglund, A., Koup, R. A., Liang, F., Lore, K.
1225 Neutrophils acquire the capacity for antigen presentation to memory CD4(+) T
1226 cells in vitro and ex vivo. *Blood* 2017; 129:1991-2001.
- 1227 141. Silvestre-Roig, C., Hidalgo, A., Soehnlein, O. Neutrophil heterogeneity:
1228 implications for homeostasis and pathogenesis. *Blood* 2016; 127:2173-2181.
- 1229 142. Giese, M. A., Hind, L. E., Huttenlocher, A. Neutrophil plasticity in the tumor
1230 microenvironment. *Blood* 2019; 133:2159-2167.
- 1231 143. Bouchery, T. and Harris, N. Neutrophil-macrophage cooperation and its
1232 impact on tissue repair. *Immunol Cell Biol* 2019; 97:289-298.
- 1233 144. Nadkarni, S., Smith, J., Sferruzzi-Perri, A. N., Ledwozyw, A., Kishore, M.,
1234 Haas, R., Mauro, C., Williams, D. J., Farsky, S. H., Marelli-Berg, F. M.,

- 1235 Perretti, M. Neutrophils induce proangiogenic T cells with a regulatory
1236 phenotype in pregnancy. *Proc Natl Acad Sci U S A* 2016; 113:E8415-E8424.
- 1237 145. Jakubzick, C. V., Randolph, G. J., Henson, P. M. Monocyte differentiation and
1238 antigen-presenting functions. *Nat Rev Immunol* 2017; 17:349-362.
- 1239 146. Apps, R., Kotliarov, Y., Cheung, F., Han, K. L., Chen, J., Biancotto, A.,
1240 Babyak, A., Zhou, H., Shi, R., Barnhart, L., Osgood, S. M., Belkaid, Y.,
1241 Holland, S. M., Tsang, J. S., Zerbe, C. S. Multimodal immune phenotyping of
1242 maternal peripheral blood in normal human pregnancy. *JCI Insight* 2020; 5.
- 1243 147. Han, X., Ghaemi, M. S., Ando, K., Peterson, L. S., Ganio, E. A., Tsai, A. S.,
1244 Gaudilliere, D. K., Stelzer, I. A., Einhaus, J., Bertrand, B., Stanley, N., Culos,
1245 A., Tanada, A., Hedou, J., Tsai, E. S., Fallahzadeh, R., Wong, R. J., Judy, A.
1246 E., Winn, V. D., Druzin, M. L., Blumenfeld, Y. J., Hlatky, M. A., Quaintance, C.
1247 C., Gibbs, R. S., Carvalho, B., Shaw, G. M., Stevenson, D. K., Angst, M. S.,
1248 Aghaepour, N., Gaudilliere, B. Differential Dynamics of the Maternal Immune
1249 System in Healthy Pregnancy and Preeclampsia. *Front Immunol* 2019;
1250 10:1305.
- 1251 148. Pique-Regi, R., Romero, R., Tarca, A. L., Sandler, E. D., Xu, Y., Garcia-
1252 Flores, V., Leng, Y., Luca, F., Hassan, S. S., Gomez-Lopez, N. Single cell
1253 transcriptional signatures of the human placenta in term and preterm
1254 parturition. *Elife* 2019; 8.
- 1255 149. Hunt, J. S. and Robertson, S. A. Uterine macrophages and environmental
1256 programming for pregnancy success. *J Reprod Immunol* 1996; 32:1-25.
- 1257 150. Cohen, P. E., Nishimura, K., Zhu, L., Pollard, J. W. Macrophages: important
1258 accessory cells for reproductive function. *J Leukoc Biol* 1999; 66:765-772.

- 1259 151. Care, A. S., Diener, K. R., Jasper, M. J., Brown, H. M., Ingman, W. V.,
1260 Robertson, S. A. Macrophages regulate corpus luteum development during
1261 embryo implantation in mice. *J Clin Invest* 2013; 123:3472-3487.
- 1262 152. Qiu, X., Zhu, L., Pollard, J. W. Colony-stimulating factor-1-dependent
1263 macrophage functions regulate the maternal decidua immune responses
1264 against *Listeria monocytogenes* infections during early gestation in mice.
1265 *Infect Immun* 2009; 77:85-97.
- 1266 153. Svensson-Arvelund, J., Mehta, R. B., Lindau, R., Mirrasekhian, E., Rodriguez-
1267 Martinez, H., Berg, G., Lash, G. E., Jenmalm, M. C., Ernerudh, J. The human
1268 fetal placenta promotes tolerance against the semiallogeneic fetus by
1269 inducing regulatory T cells and homeostatic M2 macrophages. *J Immunol*
1270 2015; 194:1534-1544.
- 1271 154. Xu, Y., Romero, R., Miller, D., Kadam, L., Mial, T. N., Plazyo, O., Garcia-
1272 Flores, V., Hassan, S. S., Xu, Z., Tarca, A. L., Drewlo, S., Gomez-Lopez, N.
1273 An M1-like Macrophage Polarization in Decidual Tissue during Spontaneous
1274 Preterm Labor That Is Attenuated by Rosiglitazone Treatment. *J Immunol*
1275 2016; 196:2476-2491.
- 1276 155. Gomez-Lopez, N., Garcia-Flores, V., Chin, P. Y., Groome, H. M., Bijland, M.
1277 T., Diener, K. R., Romero, R., Robertson, S. A. Macrophages exert
1278 homeostatic actions in pregnancy to protect against preterm birth and fetal
1279 inflammatory injury. *JCI Insight* 2021, In Press.
- 1280 156. Garcia-Flores, V., Romero, R., Schwenkel, G., Hassan, S. S., Gomez-Lopez,
1281 N. A cellular regenerative approach to prevent preterm birth: in vitro M2-
1282 polarized macrophages. *Reprod Sci* 2019; 26:74A.

- 1283 157. Garcia-Flores, V., Romero, R., Xu, Y., Miller, D., Slutsky, R., Robertson, S.,
1284 Gomez-Lopez, N. M2-polarized macrophages as a potential cell therapy to
1285 mitigate inflammation-induced preterm birth. *J Immunol* 2020; 204:145.115.
- 1286 158. Gamliel, M., Goldman-Wohl, D., Isaacson, B., Gur, C., Stein, N., Yamin, R.,
1287 Berger, M., Grunewald, M., Keshet, E., Rais, Y., Bornstein, C., David, E.,
1288 Jelinski, A., Eisenberg, I., Greenfield, C., Ben-David, A., Imbar, T., Gilad, R.,
1289 Haimov-Kochman, R., Mankuta, D., Elami-Suzin, M., Amit, I., Hanna, J. H.,
1290 Yagel, S., Mandelboim, O. Trained Memory of Human Uterine NK Cells
1291 Enhances Their Function in Subsequent Pregnancies. *Immunity* 2018;
1292 48:951-962 e955.
- 1293 159. Dominguez-Andres, J. and Netea, M. G. Long-term reprogramming of the
1294 innate immune system. *J Leukoc Biol* 2019; 105:329-338.
- 1295 160. Gomez-Lopez, N., Arenas-Hernandez, M., Romero, R., Miller, D., Garcia-
1296 Flores, V., Leng, Y., Xu, Y., Galaz, J., Hassan, S. S., Hsu, C. D., Tse, H.,
1297 Sanchez-Torres, C., Done, B., Tarca, A. L. Regulatory T Cells Play a Role in
1298 a Subset of Idiopathic Preterm Labor/Birth and Adverse Neonatal Outcomes.
1299 *Cell Rep* 2020; 32:107874.
- 1300 161. Ersland, K., Wüthrich, M., Klein, B. S. Dynamic interplay among monocyte-
1301 derived, dermal, and resident lymph node dendritic cells during the generation
1302 of vaccine immunity to fungi. *Cell Host Microbe* 2010; 7:474-487.
- 1303 162. Samstein, M., Schreiber, H. A., Leiner, I. M., Susac, B., Glickman, M. S.,
1304 Pamer, E. G. Essential yet limited role for CCR2⁺ inflammatory monocytes
1305 during Mycobacterium tuberculosis-specific T cell priming. *Elife* 2013;
1306 2:e01086.


1307 163. Schreiber, H. A., Loschko, J., Karssemeijer, R. A., Escolano, A., Meredith, M.
 1308 M., Mucida, D., Guernonprez, P., Nussenzweig, M. C. Intestinal monocytes
 1309 and macrophages are required for T cell polarization in response to
 1310 *Citrobacter rodentium*. *J Exp Med* 2013; 210:2025-2039.

1311

1312

1313

1314

1315 **FIGURE LEGENDS**


1316

1317 **FIG. 1. Localization of the fetal antigen-carrying Ly6G⁺ and F4/80⁺ cells in the**
 1318 **myometrial tissues and maternal circulation in the second half of pregnancy.**

1319 **(A)** BALB/c females were mated with B6 CAG-OVA males, and the fetuses with
 1320 surrounding myometrial tissues were collected at 10.5 days *post coitum* (dpc), 16.5
 1321 dpc, or 18.5 dpc. Representative images of the fetuses and surrounding myometrial
 1322 tissues from 10.5 dpc, 16.5 dpc, and 18.5 dpc stained with hematoxylin & eosin
 1323 (H&E) (4x magnification), and confocal microscopy imaging of DAPI+CD11b+OVA+

1324 cells (indicated by white arrows) in the myometrial tissues (100x magnification with
 1325 digital zoom) (n = 10 each). **(B)** Fluorescence-activated cell sorting (FACS) of
 1326 maternal circulating CD11b+Ly6G+OVA+ and CD11b+F4/80+OVA+ cells.
 1327 Representative fluorescence microscopy images of sorted Ly6G+OVA+ and
 1328 F4/80+OVA+ cells. Blue = 4',6-diamidino-2-phenylindole (DAPI), red = CD11b, green
 1329 = OVA (40x magnification with digital zoom) (n = 10).


Figure 2



1330
 1331 **FIG. 2. Proportions of fetal antigen-carrying Ly6G+ and F4/80+ cells in the**
 1332 **myometrial tissues and the maternal circulation throughout pregnancy. (A)**
 1333 **Representative images of the uterine horns from BALB/c females mated with B6**
 1334 **CAG-OVA males at 4.5 days *post coitum* (dpc), 10.5 dpc, 16.5 dpc, or 18.5 dpc and**
 1335 **postpartum (PP). (B & C) Representative gating strategies and proportions of (B)**
 1336 **CD45+Ly6G+OVA+ cells and (C) CD45+F4/80+OVA+ cells in the myometrial tissues**
 1337 **at 4.5 dpc, 10.5 dpc, 16.5 dpc, 18.5 dpc, and PP (n = 8 – 14 each). (D & E)**
 1338 **Representative gating strategies and proportions of (D) CD45+Ly6G+OVA+ cells**


1339 and **(E)** CD45+F4/80+OVA+ cells in the maternal circulation at 4.5 dpc, 10.5 dpc,
 1340 16.5. dpc, 18.5 dpc and PP (n = 8 – 14 each). Data are shown as box-and-whisker
 1341 plots where midlines indicate medians, boxes indicate interquartile ranges, and
 1342 whiskers indicate minimum and maximum ranges. The p-values were determined
 1343 using Kruskal-Wallis tests followed by correction for multiple comparisons ($p \leq 0.05$).
 1344 Blue lines indicate changes in the trends for the proportions of Ly6G+OVA+ and
 1345 F4/80+OVA+ cells throughout pregnancy.

Figure 3



1346 **FIG. 3. Identification of MHC class I (H2K^b or H2K^d) to determine the maternal**
 1347 **or fetal origin of Ly6G+OVA+ or F4/80+OVA+ cells in the maternal circulation**
 1348 **and myometrium. (A)** Representation of haplotypes: BALB/c females display an
 1349 **H2K^d** haplotype and B6 CAG-OVA males display an H2K^b haplotype. **(B)** Positive
 1350 BALB/c controls showing H2K^d expression and B6 controls showing H2K^b
 1351 expression in the peripheral leukocytes. **(C & D)** Flow cytometry gating strategies
 1352 and plots showing the expression of H2K^d haplotype, and the absence of H2K^b,
 1353 confirming the maternal origin of Ly6G+OVA+ and F4/80+OVA+ cells (green
 1354


1355 histograms; isotype control = grey histograms) in the myometrium and in the
 1356 maternal circulation (n = 4).



1357


1358 **FIG. 4. Immunophenotyping of fetal antigen-carrying Ly6G+ and F4/80+ cells in**
 1359 **the maternal circulation during mid and late gestation. (A)** Flow cytometry gating
 1360 strategy used to determine the Ly6G+OVA- and F4/80+OVA- cells or Ly6G+OVA+
 1361 and F4/80+OVA+ cells (green histogram = OVA; grey histogram = isotype) in the
 1362 maternal circulation. Proportions of CD11b+Ly6G+OVA- (grey histograms/dots;

1363 negative OVA expression) or CD11b+Ly6G+OVA+ (red histograms/dots; positive
 1364 OVA expression) cells and proportions of CD11b+F4/80+OVA- (grey
 1365 histograms/dots) or CD11b+F4/80+OVA+ (red histograms/dots) cells expressing (**B**
 1366 **& C**) MHC-II, (**D & E**) CD80, (**F & G**) CD86, (**H & I**) CD206, or (**J & K**) CD62L in the
 1367 maternal circulation at 10.5 days *post coitum* (dpc) and 16.5 dpc (n = 9 – 12 each).
 1368 Data are shown as box-and-whisker plots where midlines indicate medians, boxes
 1369 indicate interquartile ranges, and whiskers indicate minimum and maximum ranges.
 1370 The p-values were determined using Mann-Whitney U-tests.



1371


1372 **FIG. 5. Cytokine expression by fetal antigen-carrying Ly6G+ and F4/80+ cells in**
 1373 **the maternal circulation during mid and late pregnancy. (A)** Flow cytometry
 1374 gating strategy used to determine the Ly6G+OVA- and F4/80+OVA- cells or
 1375 Ly6G+OVA+ and F4/80+OVA+ cells (green histogram = OVA; grey histogram =
 1376 isotype) in the maternal circulation. Proportions of CD11b+Ly6G+OVA- (grey
 1377 histograms/dots; negative OVA expression) or CD11b+Ly6G+OVA+ (red
 1378 histograms/dots; positive OVA expression) cells and proportions of
 1379 CD11b+F4/80+OVA- (grey histograms/dots) or CD11b+F4/80+OVA+ (red
 1380 histograms/dots) cells expressing **(B & F)** IFN γ , **(C & G)** TNF α , **(D & H)** IL-10, or **(E**
 1381 **& I)** TGF β in the maternal circulation at 10.5 days *post coitum* (dpc) and 16.5 dpc (n
 1382 = 9 – 12 each). Data are shown as box-and-whisker plots where midlines indicate
 1383 medians, boxes indicate interquartile ranges, and whiskers indicate minimum and
 1384 maximum ranges. The p-values were determined using Mann-Whitney U-tests.



1385
 1386 **FIG. 6. Phagocytosis of placenta-derived particles by maternal Ly6G+ and**
 1387 **F4/80+ cells in mid and late murine gestation. (A)** Maternal peripheral Ly6G+
 1388 cells and F4/80+ cells were collected from wild type C57BL/6 dams mated with

1389 BALB/c males at 10.5 days *post coitum* (dpc) or 16.5 dpc and cultured with placenta-
 1390 derived particles from a GFP+ allogeneically-mated dam (n = 6 each). The uptake of
 1391 placenta-derived particles by Ly6G+ and F4/80+ cells was evaluated by flow
 1392 cytometry. **(B)** Representative gating strategy showing the uptake of GFP+ placenta-
 1393 derived particles by maternal peripheral Ly6G+ and F4/80+ cells. **(C & D)**
 1394 Proportions of active **(C)** Ly6G+ cells and **(D)** F4/80+ cells that phagocytosed GFP+
 1395 placenta-derived particles at 10.5 dpc or 16.5 dpc. Data are shown as scatter dot
 1396 plots where bars indicate the mean and whiskers indicate the standard error of the
 1397 mean. P-values were determined using Mann-Whitney U-tests. **(E)** Representative
 1398 confocal microscopy images showing maternal peripheral myeloid cells (CD11b+
 1399 cells) alone (top image) or after phagocytosing GFP+ placenta-derived particles
 1400 (bottom image). Blue indicates DAPI (nuclei), red indicates CD11b, and green
 1401 indicates placenta-derived particles. Scale bars represent 10 μ m.

Figure 7



1402

1403 **FIG. 7. Phagocytosis of cytotrophoblast-derived particles by maternal CD15+**
 1404 **neutrophils and CD14+ monocytes in the second and third trimester of human**
 1405 **pregnancy. (A)** Maternal peripheral CD15+ neutrophils and CD14+ monocytes were
 1406 collected from pregnant women in the second or third trimester and cultured with

1407 particles derived from DiO-labelled cytotrophoblast cells (n = 4 – 6 each). The uptake
1408 of cytotrophoblast-derived particles by CD15+ neutrophils and CD14+ monocytes
1409 was evaluated by flow cytometry. **(B)** Representative gating strategy showing the
1410 uptake of cytotrophoblast-derived particles by maternal peripheral CD15+ neutrophils
1411 and CD14+ monocytes. **(C & D)** Proportions of active **(C)** CD15+ neutrophils and **(D)**
1412 CD14+ monocytes that phagocytosed cytotrophoblast-derived particles in the second
1413 or third trimester. Data are shown as scatter dot plots where bars indicate the mean
1414 and whiskers indicate the standard error of the mean. P-values were determined
1415 using Mann-Whitney U-tests. **(E)** Representative confocal microscopy images
1416 showing maternal peripheral CD15+ neutrophils alone (upper image) or after
1417 phagocytosing particles derived from DiO-labelled cytotrophoblasts (bottom image).
1418 **(F)** Representative confocal microscopy images showing maternal peripheral CD14+
1419 monocytes alone (upper image) or after phagocytosing particles derived from DiO-
1420 labelled cytotrophoblasts (bottom image). Blue immunofluorescence indicates DAPI
1421 (nuclei), pink indicates CD15, red indicates CD14, and green indicates
1422 cytotrophoblast-derived particles. Scale bars represent 10 μm .

1423

1424

1425

1426

1427

1428

1429


1430

1431

1432

1433 Graphical abstract

1434



1435

Author Man